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ABSTRACT OF DISSERTATION

SYNTHESIS AND EVALUATION OF PROTEOLYSIS TARGETING CHIMERAS
(PROTACs): A POTENTIAL CHEMICAL GENETIC APPROACH TO BREAST
CANCER THERAPY
U

U

U

U

The use of small molecules to probe the function of proteins is referred to as
chemical genetics. The Proteolysis Targeting Chimera (PROTAC) is a chemical genetic
tool that contains the ligand for a target protein of interest and the recognition motif for
an E3 ubiquitin ligase attached by a linker. The PROTAC is capable of binding to and
recruiting specific target proteins to the intracellular degradation system, the ubiquitin
proteasome system (UPS). While the approach has had success it has not been optimized
to be used on a broader scale.
Optimization efforts focused on elucidating the ideal linker length between the
ligand and the E3-ligase recognition motif, the preferred location for attachment of the
linker to the two moieties, and the possibility for a dimeric PROTAC comprised of two
ligands. An estrogen receptor (ER)-targeting PROTAC was chosen as a model for
optimization attempts as the ER is known to have pathological significance in breast
cancer. Optimization of the PROTAC technology will not only provide a novel tool to
probe ER biology, but may also offer a novel approach to breast cancer therapies. The ER
targeting PROTAC constitute the 17β-estradiol (E2), as the ligand for ER and a
pentapeptide derived from HIF-1α as the E3-ligase recognition motif, joined by a linker.
Following the successful synthesis and evaluation of a number of PROTACs, it
was revealed that an optimum ER-targeting monomeric PROTAC (KC-3) has a spacer of
16 atoms between the E2 and HIF-1α pentapeptide. The spacer is attached at the C-7α
position on E2 and at the N-terminus of the HIF-1α pentapeptide. It was also established
that the PROTAC is capable of targeting the ER for degradation in a proteasome and E3ligase dependent manner, which translated to a decrease in the proliferation of MCF-7
cells with an IC 50 similar to that of tamoxifen. KC-3, in comparison with E2, displayed
lower agonistic activity on an ER-regulated downstream target, the progesterone receptor
(PR). A dimeric PROTAC more effectively binds and degrades the ER in a proteasome
dependent manner, suggesting that the dimeric ligand approach may be applied to the
design of other PROTACs.
R

R

KEYWORDS: PROTAC, Chemical-genetics, Estrogen-receptor, breast-cancer, ubiquitin
proteasome system.
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CHAPTER 1: OVERVIEW
Traditionally, the roles of proteins in cells have been elucidated using classical
genetic approaches; while this system has provided powerful tools for investigating
protein functions, there are several limitations to the classical method (reviewed in
chapter 2). Thus, a complimentary strategy termed “chemical genetics” has been
developed, which may shed light in areas where “classical genetics” has constraints.
Chemical genetics employs small molecules to interrogate the roles of proteins. The use
of small molecules confers high spatial and temporal control that is difficult to obtain by
classical genetic approaches. A major advantage of chemical genetic tools over classical
genetic methods is that chemical genetic tools can be directly translated into new
therapeutic agents. Thus, a number of approaches have been developed to identify small
molecules that modulate specific protein functions.
Recently, a novel small molecule approach termed Proteolysis Targeting
U

U

U

U

Chimeras (PROTACs) has been developed by exploiting an intracellular protein
degradation system, the ubiquitin-proteasome system (UPS). Since the pioneering work
by the Crews and Deshaies laboratories [1], the PROTAC technology has been developed
P

for a number of target proteins
P

P

[2, 3, 4, 5, 6, 7, 8, 9]

, but it has not yet been optimized as a tool
P

to be used on a broad scale. This dissertation details an attempt to elucidate an effective
PROTAC design strategy. The knowledge gained from this research will provide a
blueprint for the future development of PROTACs targeting a variety of proteins and
offer some insights into the potential of PROTACs as therapeutic agents. The PROTAC
is comprised of a ligand specific for a target protein of interest linked to an E3 ligase
recognition motif (Figure 1.1). Once bound to the target protein the E3 recognition motif
is identified and the target protein is ubiquinated and ultimately degraded by the UPS.
The work set forth in this dissertation utilizes the PROTAC approach to develop a unique
molecular probe of ER biology and to potentially develop novel therapeutic agents for
treatment of breast cancer.
A large subset of breast cancers over- expresses the estrogen receptor (ER) and is
classified as ER-positive. Due to the high levels of ER in this class of breast cancer,
therapies (antiestrogens, aromatase inhibitors) aimed at blocking the interaction of ER
with its natural ligand, 17β-estradiol (E2), have frequently been employed
1

[10, 11]
P

.
P

E3 ligase
recognition motif

E2

Linker
Ligand for protein
of interest

Target
protein

E3
Ligase

ub

E2

E3
Ligase

Target
protein

proteasome

Figure 1.1 The PROTAC
Prolonged antiestrogen treatment however, results in the development of resistance to
these therapies [12]. One principal concern related to resistance is the fact that most tumors
P

P

maintain expression of functional ERs. However, these ERs are often aberrantly
regulated; for example, unusual phosphorylation, which causes antagonists to act as
2

agonists

[12, 13, 14]
P

. Thus, mere perturbation of ER’s interaction with its ligand is not
P

sufficient, and a strategy that selectively knocks-out the ER will be useful for the
treatment of breast cancer. As such, development of an effective ER-PROTAC may
provide a novel breast cancer treatment strategy.
Goal:
The goal of this project is to develop an effective PROTAC design strategy as well as
efficient ER-degrading PROTACs.
Specific aims:
Specific aim 1: Synthesis of PROTACs that target the ER
The first aim of this study is the synthesis of a number of PROTACs. In earlier
designs of an ER-PROTAC the attachment of the linker was via an ester linkage. Initial
(unpublished) data indicated that the linkage was susceptible, in vivo, to esterase activity.
Therefore, the first attempt at optimization is to replace the ester linkage with a stable
linkage, such as a C-C linkage, by changing the location of the attachment of the linker
on 17β-estradiol. The bulk of the optimization work will be focused on the length of the
linker between the two moieties of the PROTAC to provide an adequate distance between
the E3 ligase and target protein for optimum ubiquitination. To increase the binding
opportunity with the target protein, a dimeric ligand PROTAC having two estradiols will
also be introduced.
Specific aim 2: Determine optimal PROTACs based on their ability to degrade ER in a
proteasome-dependent manner
Following the successful synthesis of PROTACs, their ability to specifically
target the ER for degradation will be evaluated in MCF-7 ER-positive cells. Western
blotting techniques as well as immunofluorescence will be employed to look at the ER
status after treatment with PROTACs.

The IC 50 for each compound will also be
R

determined.

3

Specific aim 3: Evaluate optimal PROTACs effect on ER regulated genes
Based on the information gathered from the initial ER screening the optimal
PROTACs will be tested for the ability to affect downstream targets of ER.

Copyright © Kedra C.Cyrus 2009
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CHAPTER 2: BACKGROUND

2.1 Chemical genetic approach
U

2.1.1 Introduction
Perturbation of protein function is essential in understanding the role of a
particular protein in the etiology of a specific disease. Presently, two different approaches
can be applied to study the function of a protein of interest. One method, termed
“classical genetics” involves the genetic manipulation of the target protein’s genes with
subsequent observation of phenotypic changes. The other approach involves the use of
small molecules to achieve essentially the same result and is termed “chemical genetics.”
In essence, regulation of protein can occur at three different points; at the genetic stage,
post-transcriptional stage and at the post-translational stage

[15]
P

.
P

2.2 Classical Genetics
Modifications involving the removal or activation of genes for a protein of
[16]

interest are referred to as the “genetic” or “classical genetic” approach
P

. Such
P

manipulations allow for the observation of phenotypic differences between wild-type and
altered proteins and ultimately identification of a functional role of the protein in the
diseased state. Classical genetics can be divided into two approaches, forward and
reverse.
Forward genetics starts with the random mutation (chemical or radiation) of the
DNA of a wild-type cell/organism, and following mutation the phenotypes of the mutants
and wild-types are compared. Once a phenotype (growth, behavior or morphological
change) is chosen, gene mapping is performed to identify the gene responsible [17, 18, 19, 20].
P

P

Basically, forward genetics function on an “effect to cause” basis [18, 21, 22]. On the other
P

P

hand, reverse genetics deals with the targeted deletion of a particular gene, observing
phenotypic differences when compared to wild-type and eventually delineating the role
of that specific gene [23]. Reverse genetics owes its evolution to the many progresses in
P

P

molecular biology techniques

[17, 23]
P

. However, one of the major limitations encountered
P

5

in applying the classical genetic strategy is that of lethality. Deletion of certain genes can
be fatal to the organism under investigation due to the fact that a particular gene may be
required for developmental purposes

[24]

P

. To overcome these problems new strategies
P

were implemented such as conditional knock-out/knock-in and siRNA strategies.
The use of conditional alleles has provided a level of temporal control within the
field of classical genetics. The gene of interest can be turned on or off at a particular time
based on certain conditions. Initial attempts to achieve temporal control made use of
single transgenes that were stimulated by heavy metals, temperature, interferon and
steroids
P

[24]

. However, these methods proved unreliable as there were unrelated effects
P

related to the induction or low basal activity in the absence of induction [24, 25].
P

P

Eventually a dual transgenic system was adopted that relies on the association of
two different transgenes, an “effector” and a “target”. The dual transgenic system is
classified based on the activity of the “effector”. In one case the effector is responsible
for transcriptional transactivation of the “target” transgene while in the other case, the
effector is DNA recombinase. DNA recombinase is site specific, and its action results in
rearrangement of the target gene resulting in the subsequent activation or deactivation of
the gene. Among the two most commonly used and established dual systems are the
Tetracycline regulated (TetR) and Cre/loxp systems representing the transactivation and
the site specific DNA recombinase systems, respectively [25].
P

P

As with conditional knock-out, small interfering RNA (siRNA) technology has
had a great impact on studies of protein function. Protein silencing by siRNA involves
double-stranded siRNA having average sizes of around 22 nucleotides [26]. There is twoP

P

nucleotide overhang at the 3’-end, that is specifically recognized by the RNA-induced
silencing complex (RISC) and a 5’-end that is phorsphorylated [27, 28]. Following 5’-end
P

P

phosphorylation, the siRNA forms a complex with RISC that ultimately leads to the
release of one strand (passenger strand). The resulting complex consists of the other
strand (guide strand) and RISC. This

complex is capable of binding and cleaving

complimentary mRNA and silencing its expression [26].
P

P

Despite the obvious advantages of the siRNA strategy there are a few limitations.
Among these is the lack of complete knock-down of the protein of interest as compared
to a genetic knockout; additionally, this method only blocks new protein synthesis and
6

thus, has no effect on the current protein pool [15]. Added to the above limitations are the
P

P

lack of temporal control, some reported off-target effects as well as limited in vivo uses
of siRNA [15, 17].
P

P

2.3 Chemical Genetics
The constraints of classical genetic approaches pointed to a need for alternative
methods that can control protein function in areas where traditional methods may not be
viable. Chemical genetics is a complimentary tool to classical genetics and affords
control of protein function at the post-translational level. Chemical genetics is defined as
the use of small molecules to disturb the function of protein with high temporal and
quantitative control [16, 29]. Like classical genetics, chemical genetics approaches can be
P

P

classified as forward and reverse.
Forward chemical genetics employs small molecules to look for phenotypic
changes in the biological system under examination, and ultimately leads to the
revelation of the protein that is being affected by the small molecule [29]. In the same way
P

P

classical genetics uses random mutagenesis in its forward approach, chemical genetics
uses small molecule libraries and screens for certain phenotypic changes [18]. Conversely,
P

P

reverse chemical genetics targets small molecules towards a protein of interest and once
the interaction is confirmed, the effect of the small molecule against the target is deduced
P

[18, 29, 30]

.
P

2.3.1 Advantages of chemical genetics
Chemical genetics has a number of advantages compared to classical genetics.
Among the many advantages, it is most important to note the high spatial and temporal
control provided by this strategy [29, 31]. Removal or addition of the small molecule can be
P

P

time controlled even in situations where a process is occurring on a short time scale [32].
P

P

This conditional control is only rarely available in classical genetics and when employed
often has off-target effects

[23]
P

. Moreover, chemical genetics allows for the possibility of
P

a “multi-knockout” scenario by merely adding small molecules specific for different

7

targets of interest, a scenario that is not readily accomplished using classical genetic
methods

[33, 34]
P

.
P

Classical genetic approaches, in essence, remove the entire protein product
resulting in total loss of function or, in the case of a critical gene deletion, no possible
characterization of the gene due to lethality [32]. This total loss of protein by the classical
P

P

genetic method makes it difficult to decipher effects that are due to the deletion or effects
that occur due to a precise function of the protein [20, 35]. Lethality can be avoided using
P

P

the chemical genetic approach by adjusting the dose to sublethal levels, ensuring a partial
knock-out phenotype [36].
P

P

With chemical genetics, since the small molecule directly affects the protein
under study, it can be applied to probe one function of a multifunctional protein [37]. This
P

P

selectivity of function has proven significant in the cases of kinases. Kinases have been
shown to have different roles owing to their enzymatic and protein scaffold activities.
The use of small molecule kinase inhibitor allows for blockage of the phospho-transfer
activity and leaves the protein scaffold activity untouched allowing for the categorization
of distinct activities which would be lost in the case of gene deletion
P

[38]

. Tubacin
P

provides another example of selectivity of function by a small molecule approach. This
small molecule selectivity inhibits the tubulin deacetylase activity of histone deactylase 6
while sparing the histone deacetylase activity [39, 40].
P

Knight et al,

[41]
P

P

P

showed an additional advantage of a small molecule approach:

looking at the specificity of small molecules for certain isoforms of the phosphoinositide
3-kinases (PI3K) and then deciphering the roles of the isoforms in insulin signaling. A
small molecule approach may also be effective in studying protein-protein interaction.
Recently, an inhibitor that binds tumor necrosis factor (TNF-α) and causes dissociation of
one of the members of the trimer was shown to cause inactivation of TNF-α signaling
P

[42]

.
P

Perhaps one of the most attractive aspects of chemical genetics is its ability to
simultaneously identify proteins that are “druggable” and develop small molecules that
target the protein as drug candidates [32]. As it relates to drug development, within the
P

P

field of chemical genetics there are two major requirements. First, the target has to play a

8

decisive role in the progression of the disease. Second, the target protein’s role has to be
amendable to modulation by a small molecule [43].
P

P

2.3.2 Chemical genetic libraries
U

In order to conduct chemical genetic studies the first criteria is the formation of a
small molecule chemical library. A chemical genetic library may take on a number of
different forms ranging from natural product, natural product-like, tagged libraries, to
annotated chemical libraries [18]. Following is a brief summary of some of the library
P

P

types employed in chemical genetic studies:
Natural product libraries - as the name implies these libraries are constructed
from natural sources like plants, sponges and soil [20]. The limitation of a natural product
P

P

library is that isolation and purification of active compounds is laborious and timeconsuming; even after successful isolation there is the added difficulty of structure
determination [44, 45, 46, 47]. Despite these limitations, natural products have lent a great deal
P

P

to chemical genetics efforts. Some of the better known natural products used in chemical
genetics and their targets are rapamycin, which is an immunosuppressant, trichostatin an
HDAC inhibitor and FK506 which binds FKBP12.
Natural product-like libraries – these libraries comprise small molecules whose
structure significantly resembles their natural product counterparts [48]. Because natural
P

P

products are considered “privileged” structures, meaning they contain structural motifs
that can interface with unrelated targets. Natural products are also considered
“biologically validated” and as such offer a great starting point for the creation of
libraries that should have biological activity [49, 50, 51]. These libraries can be constructed in
P

P

order to generate derivatives of the natural product [46, 52, 53, 54, 55] or to expand the utility
P

P

of a molecule to seek out unknown properties [56].
P

P

Tagged libraries – compounds in these libraries must incorporate a tag in the
molecule and these tags should confer some function to the molecule. Some of the
functions rendered by tags are: fluorescence, purification, identification, cell-permeability
and immobilization [57]. Among the better-known tags being utilized in chemical genetics
P

P

is the green fluorescence protein (GFP). Another tag that is in use is polyamide nucleic
acid (PNA) tags, which specifically bind to certain sequences on DNA. The first
9

successful use of PNA-tag small molecules was used in the exploration for inhibitors of
cathepsin L [58].
P

P

Diversity oriented synthesis (DOS) – The goal of such a library is to synthetically
mimic the diversity observed among natural products. In this sense, a library is complied
of many different types of structures without regard to any particular biological target [59].
P

P

Among the common methods applied in constructing such a library is the “split-pool/onebead-one compound” method [45]. The split-pool method involves the linking of substrates
P

P

having a desired core structure to beads which are then split into different reaction vessels
and other reactants are added. Once mixed, the beads are pooled and split again repeating
the procedure until all desired components are added [45, 59, 60, 61].
P

P

Focused library – In contrast to a DOS library, a focused library builds
compounds intended to bind to a particular target [44]. A “rational” design is favorable
P

P

when there is a known ligand for a particular protein of interest, as in the case of
receptors and enzymes [29].
P

P

2.3.3 Screening
U

Regardless of the type of library constructed, the next step in any chemical
genetic study is screening; as mentioned previously, screening can be under the banner of
forward or reverse chemical genetic approaches. When dealing with large compound
libraries high-throughput screening (HTS) is the standard procedure as it has the ability to
investigate large numbers of compounds in a short time frame. Single cell systems like
yeast/bacterial, human and mouse cells [62].
P

P

2.3.4 Forward genetic screening/ phenotype-based screening
Akin to the forward classical genetic methods, this methodology aims to find
targets that are affected when a collection of small molecules are applied to a test system.
The effects of the small molecule on a target can be ascertained by looking at phenotypic
read-outs. Read-outs may include “markers”, which measure the abundance of specific
proteins as a readout of a global cellular phenotypic effects; functional assays, which
measures cellular activities including those associated with cell division, metabolism and
10

apoptosis; or microscopic analysis, which looks at the physical nature of the cell or any
localization events of a particular marker”

[19, 62]

. Perhaps one of the best-known

P

compounds

to

be

identified

in

a

P

phenotype-based

screen

is

FK506,

an

immunosuppressant, identified by researchers in Japan in a screen of natural products
active against interleukin 2 (IL-2) [63, 64]. Later the targets of FK506 were shown to be
P

P

FKBP12 and calcenurin [65, 66].
P

P

One common method employed in phenotypic screening is the cytoblot. Cytoblot
assay is a high throughput assay that is capable of measuring DNA synthesis and
posttranslational activities such as phosphorylation. This assay was pioneered in the
Schreiber laboratory

[67]

. The assay includes the techniques of western blot and the

P

P

enzyme linked immunosorbent assay (ELISA). In short, whole cells are fixed and
detected with a specific primary antibody, followed by exposure to horseradish
peroxidase (HRP)-linked secondary antibody, quantity of product present is detected via
chemiluminescence [67]. One of the first compound-target interactions to be elucidated via
P

P

cytoblot was the monostrol-motor protein interaction. It was shown that monostrol
affected a motor protein necessary for spindle bipolarity, but had no effect on tublin [68].
P

P

Other common techniques employed in forward genetic screens involve the use of
reporter gene assays such as luciferase and automated microscopy

[18, 19]
P

.
P

2.3.5 Reverse genetic screening
U

U

This type of screening looks at the effects of small molecules on the identified
target of interest. The limitation of the reverse genetic screen is that only a few protein
targets have known small molecule partners [67]. Nonetheless, in the few cases where a
P

P

reverse genetic approach is feasible it offers tremendous insights into the functions of
proteins. According to Thorpe, this is the method widely used in pharmaceutical
companies, where small molecule effectors for proteins of interest are selectively sought
P

[69]

. There are several techniques employed in reverse genetic screening; however, for the
P

purpose of this dissertation only the Proteolysis Targeting Chimeric (PROTAC) approach
U

U

U

will be discussed in detail.
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U

2.3.6

Proteolysis Targeting Chimeras (PROTACs)
The PROTAC approach is a reverse chemical genetic approach pioneered by the

Crews and Deshaies laboratories

[1]

. While most reverse chemical genetic methods

P

P

perturb protein function simply by binding the target, the PROTAC approach induces a
chemical knock-out of the target protein. The PROTAC is a chimera having a small
molecule ligand of a target protein at one end and an E3 ligase recognition motif at the
other end. Thus, the PROTAC is designed to recruit target protein to E3 ubiquitin ligase
for polyubiquitination and subsequent degradation by the 26S proteasome (Figure 1.1).
The first PROTAC developed by Sakamoto et al. provided proof of concept for
the utility of the technology. Specifically, they developed a PROTAC composed of the
ligand ovalicin, an angiogenesis inhibitor that binds covalently to methionine
aminopeptidase-2 (MetAP-2), at one end and the IκBα-derived E3 recognition motif at
the other end. The IκBα derived peptide ligand is specifically recognized by a Skp1Cullin-F box (SCF) E3 ligase, SCFβ-TRCP [1]. This study showed that the PROTAC can
P

P

recruit otherwise non-proteasome related, MetAP-2, to the E3 ligase where it is
ubiquitinated and ultimately degraded by the ubiquitin proteasome pathway [1].
P

P

Parallel to the success of PROTACs in vitro, many practical issues were raised
regarding the general utility of the approach. They included concerns as to whether
PROTAC would work in cells, be able to target other proteins especially those related to
disease progression, and target proteins without requiring covalent attachment

[70]

. To

P

P

address such questions, PROTACs targeting the estrogen and androgen receptor, (ER)
and (AR) respectively, were developed

[70]

. These PROTACs contained the same

P

P

phosphopeptide derived from IκBα that is specifically recognized by SCFβ-TRCP
P

[70]

. The
P

study proved that the PROTACs were capable of targeting therapeutically relevant
proteins, in cells without requiring a covalent attachment to the target. However, the use
of the phosphopeptide renders the PROTACs impermeable to cells and therefore
microinjection had to be performed in order to deliver the PROTACs to cells

[70]
P

.
P

The cell permeability issues that arose from the use of the phosphopeptide were
overcome by the development of PROTACs that contain a recognition motif derived
from HIF-1α. The HIF-1α is specifically recognized by the von Hippel Lindau (pVHL)
E3 ligase complex
P

[6, 7, 8]

. Zhang et al. first employed the HIF-1α : pVHL specific
P
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interaction to target both ER and MetAP-2 (in this study the term small molecule
proteolysis inducer [SMPI] was used instead of PROTAC) [8]. Furthermore, they showed
P

P

[2, 7]

that a pentapeptide derived from HIF-1α is sufficient for recognition by pVHL
P

.
P

Similarly, Schneekloth et al. designed PROTACs having the HIF1-α derived hepta or
octapeptides that target FKBP12 and AR. In this study, they added a polyarginine tail to
further enhance cell permeability
P

[6]

. Using the HIF-1α: pVHL system, additional
P

PROTACs that target the arylhydrocarbon receptor (AHR) [3, 9], the ER and AR
P

P

[4]
P

P

have

been developed.

2.4 The Ubiquitin-Proteasome System (UPS)
The PROTAC approach exploits an intracellular protein degradation system, the
ubiquitin-proteasome system (UPS). The UPS is responsible for the selective and specific
degradation of most proteins in eukaryotic cells, including the degradation of misfolded
and many signaling proteins. Destruction of proteins via the UPS is a highly selective
process and involves two distinct and consecutive steps. The first step is the covalent
attachment of multi-ubiquitin to a target protein. The second step is the degradation of the
ubiquitin tagged protein by the 26S proteasome.

2.4.1 Ubiquitination process
U

Ubiquitin (Ub) is a highly conserved 76-amino acid polypeptide present in all
eukaryotic cells which is used to tag proteins for destruction by the UPS. The process of
protein ubiquitination involves the actions of three different enzymes referred to as E1
(activating enzyme), E2 (conjugating enzyme) and E3 (ligase) (Figure 2.2). It is
interesting to note that ubiquitinated proteins are not always targeted for degradation by
the proteasome. For example, certain proteins are tagged with one or a few ubiquitins and
then undergo endocytosis via the lysosomal pathway. Lysine 29 (K29) is believed to be
responsible for the lysosomal degradation

[71, 72]
P

. Chain formation on lysine 63 (K63)
P

does not appear to be proteolytic and may be associated with DNA repair activities,
among others
P

[72]

. Nevertheless, for proteins that are fated for destruction, a highly
P

selective series of enzymatic events have to occur. First, the C-terminal glycine residue
13

(Gly76) on Ub is activated by the E1 activating enzyme in an ATP dependent manner.
Until recently it was believed that only one E1 existed, but the latest reports seem to
[73, 74]

suggest that there may be additional E1s

. The activation reaction involves the

P

P

formation of a Ub-adenylate with the release of pyrophosphate (PPi) from ATP. The
activated Ub is then transferred to a cysteine residue on the E1 with the concomitant
liberation of AMP [75, 76, 77]. The result of this reaction is the formation of a high energy
P

P

E1-thiol-ester-Ub intermediate that is then transferred to an E2 conjugating enzyme
(Figure 2.2) [75, 76, 77].
P

P

In comparison to the E1 enzyme, there are known to be a number of E2s. As
many as eleven have been reported in the yeast genome and that number is thought to be
greater in higher organisms [78]. The E2s are referred to as the Ub carrier proteins or Ub
P

P

conjugating enzymes as they accept the activated Ub from E1 and facilitates its
attachment to the target protein in conjunction with E3s (Figure 2.2). The E2s may serve
as a bridge between the target protein and an E3 or may transfer the Ub to an E3, which
will subsequently tag the protein.
The E3s are responsible for the specific recognition of a particular substrate and
can be either a protein or a protein-complex [79]. The E3 reaction involves two events, the
P

P

Ub signal dependent binding of the E3 to substrate and the covalent attachment of Ub to
the target protein
P

[78]

. Two of the most widely studied classes of E3s are the HECT
P

(Homologous to the E6-AP C-Terminus)

[80]

P

Interesting New Gene) finger domain E3s.
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P

domain E3s and the RING (Really
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Figure 2.2 The Ubiquitin - Proteasome System
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Ub

The HECT domain E3s has a conserved cysteine residue to which Ub from the E2
is transferred, forming another high energy thiol ester bond [81]. These E3s then transfer
P

P

the activated ubiquitins to a lysine residue, often lysine-48 (K48), on the substrate. A
member of the HECT E3 family is NEDD4 that targets the sodium channel in the kidney
epithelium
P

[82]

. Unlike HECT E3s, the RING finger family of E3s acts as a bridge
P

between the substrate and E2. They do so by binding to both the E2 and the substrate
thereby, bringing the two within a proximity where the E2 is able to directly transfer Ub
to the K48 residue of the substrate

[83]

P

. RING E3s are monomers or homodimers
P

containing both the RING finger domain and the substrate recognition site in one
molecule. Examples include mdm2, which targets p53 [84, 85] and parkin, which targets
P

P

synaptic vesicle-associated protein, CDCrel-1 [86, 87]. A number of RING E3s are part of
P

P

larger multisubunit complexes such as the SCF complex, which is involved in the
degradation of IkB

[88]

, the APC (Anaphase Promoting Complex, responsible for

P

P

degrading cell cycle regulators [89] and the VBC (von-Hippel Lindau(VHL)-Elongins B
P

P

and C)-Cul2-Rbx1 E3 ligase complex associated with the degradation of Hypoxia
Inducible Factor (HIF)-1α

[90, 91, 92]

.

P

P

2.4.2 VBC-Cul2-Rbx1 E3 ligase complex and HIF-1α
U

The unique interaction of HIF-1α with the VBC E3 ligase has been well
characterized. HIF is important for normal development and plays a pivotal role in
pathophysiological responses to low oxygen (hypoxic) conditions, as well as in tumor
growth and angiogenesis [93]. HIF is a heterodimer consisting of α and β subunits that
P

P

binds to DNA under hypoxic conditions. The β subunits are constitutively expressed
whereas the alpha subunit is highly regulated. Under normal oxygen (normoxia)
conditions, the alpha subunits are rapidly targeted for polyubiquitination by pVHL and
subsequently degraded by the proteasome.
pVHL is a tumor suppressor protein whose mutation is associated with the
development of VHL disease, a hereditary cancer characterized by the presence of highly
vascularized tumors
P

[94]

. pVHL binds to a specific region on HIF-1α known as the
P

oxygen-dependent degradation domain (ODD) [95, 96]. There are two distinct regions that
P
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P

can operate independently of each other: one at the C-terminal (C-ODD) and the other at
the N-terminal (N-ODD) [97, 98]. The interaction of pVHL at these domains is regulated by
P

P

the hydroxylation on specific proline residues within the ODD proline 402 (Pro 402) in
the N-ODD and proline 564 (Pro 564) in the C-ODD [95, 99]. Experiments conducted using
P

P

various peptide lengths within the ODD indicated that the C-ODD region in HIF-1α is
important for the binding of pVHL, while the N-ODD region only increases binding
slightly [100]. Further, mutation studies demonstrated that there is a highly conserved motif
P

P

containing a proline residue (Pro-564) and this motif is critical for the interaction with
pVHL. Later, it was shown that hydroxylation of the proline initiates the ubiquitination
and degradation of HIF-1α [99]. In the present studies, this interaction has been exploited
P

P

in designing PROTACs that target the ER for proteasomal degradation.

2.4.3 The Proteasomes
U

The 26S proteasome is a hollow cylindrical-shaped mega structure (2.4 MDa)
containing a 20S subunit referred to as the catalytic core and the 19S regulatory subunit
P

[101]
P

(Figure 2.2). There are two types of proteasomes, the regular (or constitutive)

proteasome and the cytokine-inducible immunoproteasome. The immunoproteasome is
thought to be associated with the generation of MHC class I antigens [102].
P

P

The 20S catalytic subunit consists of two sets of heptameric α and β subunits
arranged as four stacked rings. The two outer rings are each made up of seven α subunits
while the two inner rings each contain seven β subunits [103]. Three of the β subunits, β1,
P

P

β2 and β5, are catalytically active and their proteolytic activities are unique
P

[79]

. β1
P

displays caspase-like (C-L) activity, cleaving after acidic residues, β2 cleaves after basic
residues (trypsin-like activity, T-L) and β5 cleaves after bulky hydrophobic residues
(chymotrypsin-like activity, CT-L)

[104]

. In response to γ-interferon signaling these β

P

P

subunits are replaced with three alternative subunits: β1 replaced with β1i/LMP2, β2 with
β2i/MECL-1/LMP10 and β replaced with β5i/LMP7 [105] to form the immunoproteasome.
P

P

As it relates to the function of the α subunits, it has been shown that the N-termini
of the α subunits block entry of protein substrates to the proteolytic cavity thus acting as a
gate to prevent unwanted degradation [106]. The 20S proteasome only becomes accessible
P

P
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upon the binding of the 19S regulatory subunit. The 19S regulatory particle consists of a
9-protein lid for polyubiquitin binding, and a 10-protein base that interacts specifically
with the α ring. The 19S base binds to and displaces the N-terminal of the α subunits

[107]

,

P

P

wheras the 19S-lid regulatory particle is involved in the recognition, binding and
deubiquitination of polyubiquitinated substrates

[108, 109, 110, 111]

. The 19S-base contains

P

P

several ATPases and deubiquitinases [112]. Once the substrate enters the catalytic core it is
P

P

degraded into smaller peptides.

2.5 Estrogen receptors (ER) and Breast Cancer
2.5.1 Estrogen receptor (ER)
U

The estrogen receptors (ER) belong to the family of nuclear receptors, which is
one of the largest classes of proteins having over 70 known members. The ER is more
specifically referred to as a steroid hormone nuclear transcription factor. Currently, two
types of estrogen receptors exists ERα and ERβ. The ER (ERα) was cloned in 1986 [113]
P

P

approximately 40 years after Jensen indicated the possible role of a receptor that
specifically binds 17β-estradiol (E2) [10, 11, 114]. The second receptor ERβ was cloned in
P

P

1996 [115].
P

P

The ER contains a number of functional domains [116, 117, 118, 119] as depicted in
P

P

Figure 2.3. There is an N-terminal A/B domain that is not well conserved among the
steroid receptors. Within the A/B domain is a transactivation function (AF-1) responsible
for ligand-independent transcriptional activation. The C domain comprises the DNA
binding domain, which is the most highly conserved domain within the nuclear receptor
family. The DBD is responsible for the high specificity, high affinity binding of the ERs
to their estrogen responsive elements (EREs)

[120, 121, 122]
P

. Within the DBD there are two
P

zinc finger motifs. While there are a number of similarities among zinc fingers within the
nuclear receptor family, mutagenesis studies indicate that one of the zinc fingers lends
specificity to the individual receptors by binding to specific residues in the major groove
of DNA; the other zinc finger works to stabilize the aforementioned interaction [123, 124]. In
P
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P

addition to the DNA binding domain the C domain also contains a dimerization
functionality as well as a nuclear localization signal [121, 125, 126].
P

A/B

C

N-terminal domain

DBD

D

P

E

F

LBD

AF-1

AF-2

Hinge

Figure 2.3 The functional domains of the estrogen receptor (ER): DBD- DNA
binding domain, LBD- ligand binding domain, AF-1, 2 (transcription activation function
1 and 2).

The D domain is a non-conserved, hydrophilic domain that acts a hinge between
the DBD and the ligand binding domain (LBD). This domain may direct the DNAbinding activities of the receptor while the hinge region may also play a role as an anchor
for co-repressor proteins [10, 122, 127, 128]. The ligand binding domain (LBD) is located in the
P

P

C-terminal E region which contains a hydrophobic pocket formed as a result of 12α
helices; the hydrophobic pocket is important for ligand binding [128, 129, 130]. The LBD is
P

P

less well conserved in comparison to the DBD. Within the E region there is also a liganddependent dimerization function, a ligand-dependent nuclear localization signal, heat
shock protein 90 (HSP90) binding utility and another activation function (AF-2), which is
ligand-dependent [128, 130]. The F region at the C terminal domain is involved in a number
P

P

of activities including the selection of agonists or agonists, crosstalk between other
signaling pathways, regulation of proteasomal degradation and possible blockade of
dimerization [131, 132, 133, 134].
P

P
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It must be noted that while the DBD of ERα and ERβ are almost identical (95%
amino acid identity), and their LBDs are moderately identical, approximately 56%, while
they differ markedly in their AF-1 (around 21% amino acid identity)

[135, 136]

; the AF-1 of

P

P

ERβ seems to be inconsequential in regulating reporter gene expression

[137]

. Additionally

P

P

the hinge and the F region are not conserved among the receptors [138]. The ERs also
P

P

differ in their tissue distribution. ERα is predominantly expressed in the breast, vagina
and uterus while ERβ is more highly expressed in the gastrointestinal system, central
nervous system, lungs, cardiovascular system, immune system and bone, but is not highly
expressed in breast tissues
P

[135]

. In certain breast cancers, the ERα is over expressed;
P

therefore these cancers are termed ER-positive or hormone sensitive.

2.5.2 Mechanisms of action of ERs
U

U

The estrogen receptor is a member of the ligand activated transcription factor
family. In response to ligand binding, the ER binds to EREs, initiating transcription of
target genes
P

[139, 140]

. The cellular localization of the unliganded ER has been
P

controversial and it seems that the location of the ER plays a role in ER actions. It is
thought that the unliganded ER predominately resides in the nucleus, but there is also a
[139, 141, 142, 143]

pool of ERs located in the cytoplasm and at the membranes

.

P

P

Genomic actions of ER
In the “classical or genomic” mechanism, E2 diffuses through the membrane and
binds to ER, resulting in a conformational change of the ER that allows it to dissociate
from chaperones, dimerize and bind to the ERE on the target gene’s promoter. Once
bound to the ERE, AF-1 and AF-2 are responsible for recruiting co-activators from the
p160 family, steroid receptor co-activators 1, 2 and 3 (SRC1,2,3). Other factors
responsible for chromatin remodeling, that interact with the general transcription
machinery in order to initiate transcription of the target genes are also recruited [144].
P

P

Some of the genes transcribed via the ER genomic action include, trefoil factor
(pS2/TFF1) and vascular endothelial growth factor (VEGF) [145].
P
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Figure 2.4 Mechanism of ER actions

Nongenomic actions
ERs can also act independently of ERE binding. This non-genomic action of the
ER occurs via protein-protein interactions with other transcription factors. Approximately
35% of target genes are transcribed in this manner [145]. For example, ER action through
P

P

AP-1 activation is responsible for the transcription of such genes as insulin growth factor1 (IGF-1), cyclin D1 and collagenase [145, 146, 147]. Opposite effects at AP-1 sites have been
P

P
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indicated for ERβ

[148, 149]

. ER also interacts via a non-classical mechanism with ER-

P

P

specific protein-1 or stimulating protein-1 (SP-1) to mediate transcription of target genes
P

[145, 150]

. Interaction at SP-1 sites involves the complex binding to GC- rich regions within
P

the promoters of target genes enabling transcription of such genes as retinoic acid
receptor 1α (RXRα), insulin growth factor binding protein -4, low-density lipoprotein
(LDL) receptor and cathepsin

[151, 152, 153]
P

.
P

Non-genomic actions
Membrane or cytoplasmic ERs are also believed to be responsible for the rapid
non-classical/ non-genomic actions of ER. In this case, ligand binding to these receptor
pools result in the activation of a number of signaling pathways. One such example is the
mitogen activated protein kinase pathway (MAPK) [154, 155]. Estrogen bound membrane
P

P

ER has also been shown to activate the insulin-like growth factor receptor-1(IGF-1R) and
epidermal growth factor receptor (EGFR) cell signaling cascades [12, 156].
P

2.5.3
U

P

ER-positive breast cancer and treatment
Breast cancer is the second leading cause of cancer death among women in

industrialized countries. According to the 2009 cancer statistics an estimated 192, 370
women will be diagnosed with breast cancer and over 40, 000 will die from the disease
P

[157]

. Approximately 70% of breast cancer diagnosed is ER-positive. The length of
P

exposure to estrogen has been shown to play a role in increasing the chance of
developing breast cancer. Most of the genes that are upregulated by the ER are involved
in proliferation and as such have a direct effect on the progression of breast cancer

[158]
P

.
P

Thus, current breast cancer therapies aim to inhibit the action of the ER by blocking the
production of E2 (eg. aromatase inhibitors)

[159, 160]
P

P

or blocking the binding of estrogen to

the ER (eg. antiestrogens) [161, 162, 163, 164, 165, 166] .
P

P

One of the oldest and most widely used antiestrogen is tamoxifen (Figure 2.5).
Tamoxifen is classified as a selective estrogen receptor modulator (SERM) having
antagonist activity in the breast, but agonist activity in the uterus and bone

[167, 168]
P

. It has
P

been shown that the binding of tamoxifen to the ER leads to a conformational change that
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is different from E2 binding [12]. Specifically, the binding of tamoxifen within the ER’s
P

P

binding pocket results in a conformational change that results in the pocket not being
sealed properly. This conformational change deters the binding of coactivators resulting
in the inactivation of AF-2 function. The inhibition of AF-2 function prevents
transcription of genes that are dependent of AF-2-ER functionality

[169]

. The breast tissue

P

P

is reliant on AF-2-ER mediated gene transcription, whereas the uterus is reliant on the
ER-AF-1 function; this is why tamoxifen acts as an antagonist in breast, but as an agonist
in the uterus, where the AF-2 function is not important

[170, 171]
P

.
P

Tamoxifen, by virtue of its SERM nature, has been linked to an increase in the
chances of developing endometrial cancer [172]. The main problem with Tamoxifen and
P

P

other antiestrogenic compounds, as well as aromatase inhibitors
P

[173]

, is the eventual
P

development of resistance after prolonged use. Close to 100% of patients with metastatic
disease and about 40% of patients receiving adjuvant therapy succumb to resistance and
eventually die from the disease [12]. There have been several mechanisms proposed for
P

P

the development of resistance to these therapies including, increased ER-HER2 crosstalk
P

[174, 175]

; elevated levels of EGF, responsible for mediating autocrine growth pathways in
P

resistant cells
P

[176]
P

as well as increased phosphorylation of Ser 118 on the ER
P

[13]

.
P

Phosphorylation at Ser 305 has recently been implicated in the causation of resistance as
well [14]. It is important to note that loss of ER may not be a factor in development of
P

P

resistance as both tamoxifen-resistant and primary breast tumors retain high levels of ER
and is affected by pure antagonists

[176, 177]
P

.
P

Another antiestrogen, termed a pure antagonist, is Faslodex® (ICI182,780). At
the time of its discovery, ICI182,780 displayed no estrogenic activity and was developed
as an alternative second line therapy to treat patients that were no longer affected by
tamoxifen treatment [178]. While its mode of action is not clearly understood, ICI182,780
P

P

seem to cause a down regulation of the ER [179]. Recent studies seem to suggest that
P

P

ICI182,780 may not be a pure antagonist after all, as it displays agonist activity in
Hippocampal Neurons

[180]
P

. While the effect is a positive one, there might be other yet
P

undiscovered agonistic activities of this drug that may have negative impacts.
Given the role of ER in the progression of breast cancer, alternative methods are
needed to delineate unknown roles or unknown targets that may be associated with the
23

ER. Thus, the employment of a PROTAC that selectively knocks-down the ER is
proposed as a novel probe to elucidate ER biology. In addition the PROTAC strategy
may provide a new therapeutic candidate for treating ER-positive breast cancers.

Figure 2.5 Structures of Estradiol (E2) and ER antagonists

Copyright © Kedra C.Cyrus 2009
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CHAPTER 3: CHEMISTRY- SYNTHESES OF PROTACs

3.1 Introduction
While the PROTAC technology has been developed to target proteins for
degradation and may be a valuable tool to investigate protein functions, a detailed
PROTAC optimization strategy has never been explored. As such, the main objective of
this project is to optimize the PROTAC technology for broad applications. The ER
targeting PROTAC was used as the model in this optimization effort since the first
generation of cell permeable PROTACs were developed based on ER-targeting strategy.
In addition, the ER is the main therapeutic target for breast cancer therapy and
optimization of a PROTAC that specifically targets the ER may pave the way to develop
a novel ER antagonist that acts differently from any other ER antagonists clinically
available. The information gathered from this optimization study may also be useful for
the design of PROTACs that target other proteins.
The first generation ER targeting PROTAC (Figure 3.1) involved the
attachment of a linker at the O-17 position on E2, the natural ligand of the ER (Figure
3.1). The successful development of the first ER targeting PROTAC provided proof of
concept for targeting the ER by this approach; however, while this PROTAC was able to
cause degradation of the ER in vitro, the ester linkage proved to be problematic in initial
in vivo studies. The linkage was apparently cleaved off as a result of intracellular esterase
activity resulting in tumor growth (unpublished data).
In this current study, three main areas were focused on to improve the PROTAC:
First, in order to address the issue of linker cleavage, the ester linkage was replaced with
a carbon-carbon linkage through the C-16 and C-7 positions of E2 (Figure 3.1). Second,
PROTACs were synthesized with varying lengths, in order to determine an optimal
distance between E3 ubiquitin ligase (pVHL) and the protein of interest (ER). Third, a
dimeric PROTAC having two estradiols at both ends of the pVHL recognition motif was
developed in order to increase the chances of recruiting the ER for ubiquitination and
ultimately degradation.
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In this chapter the synthetic routes, reaction details and structural analysis of
intermediates leading up to and including PROTAC synthesis are presented.

Figure 3.1 Structure of the original ER-PROTAC (E2-Penta): highlighting the O-17
ester linkage and the C-16 and C-7 locations for C-C bond formation.

General: Unless otherwise noted, all reactions were carried out under nitrogen or
argon in freshly distilled solvents, oven-dried glassware. Reagent grade solvents were
used. Tetrahydrofuran (THF) was distilled from sodium/benzophenone. Methylene
chloride (CH 2 Cl 2 ) was distilled from calcium hydride. Anhydrous diethyl ether was
R

R

R

R

R

R

purchased from Fisher and used without further distillation. All other reagents were
purchased from Sigma-Aldrich and used without further purification. Peptides were
purchased from Advanced Chem Tech (Louisville, KY). Reactions were monitored by
TLC using E. Merck 60F254 pre-coated silica gel plates. Flash column chromatography
was performed using E. Merck silica gel 60 (particle size 0.040-0.063mm). 1H NMR
P

P

spectra were recorded on a Varian 300MHz or 500MHz spectrometers. Mass spectral
analyses were carried out by the University of Kentucky Mass Spectrometry Facility.
3.2 pVHL recognition motif derived from HIF-1α
U

One of the components of the PROTAC is the degradation signal derived from the
HIF-1α protein. The amino acid sequence recognized by pVHL consists of an (ODD)
containing the highly conserved sequence (Met-Leu-Ala-Pro-Tyr-Ile-Pro-Met). In
26

previous work it was shown that a pentapeptide derived from HIF-1α ODD domain is
sufficient to be recognized by pVHL [7].
P

P

The pentapeptide was synthesized following conventional peptide synthesis
approaches. Briefly, for pentapeptide-1, the synthesis began with the coupling of a Cterminal protected isoleucine to a tyrosine protected at both its N-terminal and its
hydroxyl

with

respectively,

Fmoc

the

(9-fluorenyl-methoxy-carbonyl)

coupling

reagents

HBTU

and

tertiary-butyl

(t-Bu)

(2-(1H-Benzotriazol-1-yl)-1,1,3,3-

Tetramethyluronium hexafluorophosphate) and HOBt (N-Hydroxybenzotriazole), along
with DIPEA (N,N-Diisopropylethylamine) as a base in CH 2 Cl 2 . Following successful
R

R

R

R

coupling, the Fmoc group was removed with 20% piperidine in DMF (N,N-Dimethyl
formamide) and the process was repeated with the remaining Fmoc-protected amino
acids to give pentapeptide-1 (Figure 3.2). t-Bu protecting group on tyrosine was either
removed prior to or after full assembly of the PROTAC. A mutant pentapeptide
(pentapeptide-2, Figure 3.2) containing nor-leucine in place of the hydroxyproline residue
was also synthesized following a similar procedure described above; this will serve as a
negative control for pentapeptide-2. In order to study whether linker attachment to the Cor N-terminus of the pentapeptide is important for PROTAC activity, an additional
pentapeptide that was protected at the N-terminal with a benzyloxycarbonyl (cbz/Z)
group and a free carboxylic acid at its C-terminus was also synthesized (Figure 3.2).
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Figure 3.2: Structures of pentapeptide-1 to 3
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3.3 Synthesis of C-16α PROTACs
U

One of the primary goals of this project was to synthesize a PROTAC that had a
less labile linkage by eliminating the ester linkage and adding hydrolytically stable C-C
bond. The task was to find a place on E2 that will allow for attachment of the linker
without disrupting the E2- ER interaction significantly. Another critical issue with the
original ER-targeting PROTAC was the loss of the 17-OH which was used attach the
linker. It has been reported that the OH is important for the binding activity of E2 to ER
P

[181]

; therefore, any modification that can spare the hydroxyls is most desirable in
P

designing an ER targeting compound based on the E2. Derivatization at the C-16α
position on E2 has been previously reported in the construction of a Geldanamycin
tagged E2 compound that maintained good E2-ER interaction

[182]
P

.
P

In order to attach the pentapeptide to the C-16α position and extend the length of
the linker attaching the two different moieties a “handle” had to be placed on the E2 that
would allow for further extension. A scheme, (Scheme 3.1), similar to the one reported
in

[182, 183]
P

P

was followed for synthesis of a “free amine handle” attached to the C-16α

position of E2. The scheme allowed for the formation of the desired α-alkylation at the C16 position, a stereochemistry that is important for the high binding affinity to the ER
P

[184]

. The handle, can be further extended via amide bond formation.
P
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Scheme 3.1- Synthesis of C-16α handle

Synthesis of C-16α PROTACs K-1 and K-2
U

Following the successful synthesis of the free amine handle the length was
further extended using glycine, and an eight carbon linker, disuccinimidyl suberate
(DSS). The pentapeptide was then attached to give the fully assembled protected
PROTACs, after deprotection of protecting groups the C-16 PROTACs were isolated as
K-1 and K-2 (Scheme 3.2).
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Scheme 3.2 synthesis of C-16α PROTACs K-1 and K-2
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Reaction details and NMR data for the synthesis of C-16α PROTAC’s handle
U

Compound 2: Estrone (1) (4.00 g, 0.0148 mol) and imidazole (3.00 g, 0.044 mol) were
dissolved in 40 mL (CH 2 Cl 2 ) and 15 ml DMF. tert-Butyldimethylsilyl chloride
R

R

R

R

(TBDMS-Cl) (6.70g, 0.044mol) was added, and the solution was stirred at room
temperature, after 2 hours the solution was filtered through filter paper and solvent
removed, the residue was dissolved in CH 2 Cl 2 and column chromatography was
R

R

R

R

performed using (5:1 hexanes:ethyl acetate (Hex:EtOAc)) to yield a white solid (5.62 g,
99%).
1

H NMR (CDCl 3, 500 MHz): δ 0.19 (s, 6H), 0.91 (s, 3 H), 0.98 (s, 9H), 2.84-2.87 (m,

P

P

R

R

2H), 6.57 (d, 2.5 Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1 H), 7.13(d, J = 8 Hz, 1H)
Compound 3: Under nitrogen, dry THF (6 mL) was added to a flask containing (2)
(400.0 mg, 1.04 mmol) and the solution was cooled to 0 °C. Lithium diisopropylamide
(LDA) (0.80 mL, 1.45 mmol) was then added (drop-wise) and the solution was stirred for
an additional 0.5 h at 0 °C. The reaction was then cooled to -20 °C using an external bath
(sodium chloride (NaCl), ice), and electrophile (1,4 dibromo-2-butene) (440.0 mg, 2.08
mmol, in 1 mL of THF) was added (drop-wise). The reaction mixture was stirred at -20
°C for an additional 4 hrs, water was then added and mixture was extracted with three 50
ml portions of EtOAc. The organic phase was washed with brine and dried over sodium
sulfate (Na 2 SO 4 ). Following filtration and solvent removal, the residue was dissolved in
R

R

R

R

CH 2 Cl 2 and column chromatography was performed using (10: l Hex: EtOAc) to give a
R

R

R

R

thick yellow oil. Reaction was repeated 4 times with the same amounts to yield (3) (1.2 g,
45%).
1
P

H NMR (CDCl 3 , 500 MHz): δ 0.19 (s, 6 H), 0.96 (s, 3 H), 0.98 (s, 9 H), 2.82-2.85 (m, 2
P

R

R

H), 3.95 (d, J = 6.6 Hz, 2 H), 5.74 – 5.78 (m, 2 H), 6.57 (d, J = 3 Hz, 1 H), 6.63 (dd, J =
8.5, 2.5 Hz, 1H), 7.12 (d, 1 H, J = 8.5 Hz, 1 H).
Compound 4: Sodium azide (NaN 3 ) (520 mg, 7.64 mmol) was added to a flask
R

R

containing (3) (960 mg, 1.91 mmol) and the contents were dissolved in THF (25ml), 2 ml
of water and 2 ml DMSO. The mixture was stirred at room temperature for 2 hrs after
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which, water was added and extraction performed with EtOAc. The organic phase was
washed with brine and dried over (Na 2 SO 4 ). Following filtration and solvent removal,
R

R

R

R

residue was dissolved in CH 2 Cl 2 and column chromatography was performed (10: l Hex:
R

R

R

R

EtOAc) to give (4) as a pale yellow oil (889 mg, 96 %).
1

H NMR (CDCl 3 , 300MHz): δ 0.19 (s, 6 H), 0.96 (s, 3 H), 0.98 (s, 9 H), 2.83 (m, 2H),

P

P

R

R

3.73 (d, J = 6.3 Hz, 2 H), 5.47-5.80 (m, 2 H), 6.56 (d, J = 2.4 Hz, 1H), 6.62 (dd, J = 8.3,
2.4 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1 H).
Compound 5: Methanol (MeOH) was added to (4) (510 mg, 1.06 mmol) and cooled to 0
°C, after 10 min sodium borohydride (NaBH 4 ) (120 mg, 3.19 mmol) was added and
R

R

reaction stirred for an additional 2.25 hrs. MeOH was removed under reduced pressure,
water was added and EtOAc was used for extraction. The organic fraction was washed
R

R

with brine and dried over (Na 2 SO 4 ). Product was isolated as a white solid (250 mg, 49%)
R

R

R

R

following column chromatography (10: l Hex: EtOAc). * Attempts to simultaneously
reduce the azide and ketone using LAH were unsuccessful; therefore sequential reduction
steps were employed: NABH 4 - ketone reduction and LAH-azide reduction.
R

1

R

H NMR (CDCl 3 , 300MHz) δ 0.19 (s, 6H), 0.82 (s, 3 H), 0.99 (s, 9H), 2.80 (m, 2 H),

P

P

R

R

R

R

3.33 (d, J = 7.8 Hz, 1H), 3.74 (d, J = 6.6 Hz, 2H), 5.56-5.88 (m, 2 H), 6.55 (d, J = 2.7
Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1H).
Compound 6: (5) (250 mg, 0.52 mmol) was dissolved in dry THF (15ml) and then
cooled to approximately -10°C. Excess lithium aluminum hydride (LAH), (100 mg, 2.60
mmol) was slowly added and the reaction was stirred for 2 hours. Reaction was then
extracted with CH 2 Cl 2 dried over Na 2 SO 4 and purified via column chromatography
R

R

R

R

R

R

R

R

(95:5 CH 2 Cl 2 : MeOH), (6), (159mg, 67%) was obtained as white solid.
R

P

1

R

R

R

H NMR (CDCl 3 , 300 MHz) δ 0.19 (s, 6H), 0.82 (s, 3 H), 0.98 (s, 9H), 2.78 - 2.80 (m, 2
P

R

R

H), 3.21-3.28 (m, 3 H) 5.58-5.63 (m, 2 H), 6.55 (d, J = 2 Hz, 1 H), 6.61 (dd, J = 8.1, 2.4
Hz, 1 H), 7.12 (d, J = 8.1 Hz, 1H).
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Reaction details NMR AND Mass spectrometry data for the synthesis of C-16α PROTACs
U

K-1 and K-2
Compound 7: Fmoc-Gly-OH (107mg, 0.360mmo1), HBTU (170 mg, 0.45 mmol) and
HOBt (69 mg, 0.45 mmol) was added to a flask containing the free amine (6) (136 mg,
0.30 mmol). The reagents were dissolved in CH 2 Cl 2 and excess DIPEA (310μl) was
R

R

R

R

added. The reaction was stirred at room temperature overnight. Column chromatography
was performed using (1:1 Hex: EtoAC) to yield (7), (105 mg, 47%) as a clear oil.
1

H NMR (CDCl 3 500 MHz) δ 0.19 (s, 6H), 0.79 (s, 3H), 0.98 (s, 9H), 2.78 – 2.81 (m,

P

P

R

R

2H), 2.82 (s, 4H), 3.25 (d, J = 7 Hz, 1H), 3.77-3.89 (m, 4H), 4.23 (t, J = 6.7 Hz, 1H), 4.43
(d, J = 7 Hz, 2H), 5.47 - 5.70 (m, 2H), 6.27 (t, J = 5.4 Hz, 1H), 6.55 (d, J = 2.4 Hz, 1H),
6.62 (dd, J = 8.5, 2.4, 2.7 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1H),7.30 – 7.33 (m, 2H), 7.39 –
7.42 (m, 2H), 7.60 (d, J = 7.5 Hz, 2H), 7.77 (d, J = 7.5 Hz, 2H)
Compound 8: 20% piperidine in DMF (1.5 ml) was added to (7) (105mg, 0.143mmol)
and the reaction was stirred at room temperature for 40 mins. Solvents were removed
under high vacuum and column chromatography was performed using (95:5 CH 2 Cl 2 :
R

R

R

R

MeOH) to remove by products. The column was washed with MeOH to isolate (8)
(49mg, 67%) as a white solid. Free amine confirmed by Kaiser test.
Compound 9: Disuccinimidyl suberate (DSS) (70.0 mg, 0.191 mmol) was added to a
flask containing (8) (49mg, 0.095mmol) and the contents were dissolved in DMF (2.5 ml)
and stirred at room temperature overnight. DMF was removed under high vacuum and
(95:5 CH 2 Cl 2 : MeOH) was used to purify the product via column chromatography. (9)
R

R

R

R

(27mg, 38%) was isolated as an oil.
P

1

H NMR (CDCl 3 300 MHz) δ 0.18 (s, 6H), 0.80 (s, 3H), 0.97 (s, 9H), 2.61 (t, J = 7.2 Hz,
P

R

R

2H), 2.78 – 2.84 (m, 6H), 3.27 (d, J = 7.2 Hz, 1H), 3.75-3.81 (m, 2H), 3.90 (d, J = 5.4
Hz, 2H), 5.44 - 5.70 (m, 2H), 6.33 (t, J = 5.4 Hz, 1H), 6.48 (t, J = 4.8 Hz, 1H), 6.55 (d, J
= 2.4 Hz, 1H), 6.62 (dd, J = 8.5, 2.7, 2.4 Hz, 1 H), 7.11 (d, J = 8.5 Hz, 1H)
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Compound 10: Pentapeptide-1(no t-Bu), (26.0 mg, 0.035 mmol) was added to (9) (27.0
mg, 0.035 mmol), dissolved in DMF (2 ml) and stirred under N 2 overnight at room
R

R

temperature. Following removal of DMF under high vacuum, (95:5 CH 2 Cl 2 : MeOH) was
R

R

R

R

used to purify product as a white solid (22.5 mg, 47%).
1

H NMR (CDCl 3 500 MHz) δ 0.18 (s, 6H), 0.79 (s, 3H), 0.80-0.84 (m, 6H), 0.89-0.93

P

P

R

R

(m, 6H), 0.97 (s, 9H), 2.78 – 2.81 (m, 2H), 3.11 (dd J = 7, 3 Hz, 2H), 3.26 (d, J = 7 Hz,
1H), 3.55 (dd, J = 10.7, 2.7 Hz, 1H), 3.70-3.81 (m, 4H), 3.85 (d, J = 6 Hz, 2H), 4.36 –
4.55 (m, 6H), 4.60 (t, J = 7 Hz, 1H), 5.13 (s, 2H), 5.45 - 5.49 (m, 1H), 5.66 – 5.69 (m,
1H), 6.54 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.5, 2.5, Hz, 1 H), 6.87 (d, J = 8.5 Hz, 2H),
6.95 (d, J = 8.5 Hz, 1H), 7.09 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 6.5 Hz, 1H), 7.30 – 7.38
(m, 6H), 7.39 (d, J = 7 Hz, 1H), 7.55 (d, J = 7.5 Hz, 1H)
K-1: To obtain K-1 the TBDMS protecting group was removed. THF (1ml) was added to
(10) (22.5 mg, 0.016 mmol), followed by tertiary butyl ammonium fluoride in THF
(TBAF) (14 μl, 0.048 mmol) and reaction was stirred at room temperature for 20 mins.
Column chromatography was performed using (95:5 CH 2 Cl 2 : MeOH) initially and then
R

R

R

R

increasing MeOH concentrations to isolate K-1 (20.6 mg, 100%) as a white solid.
1
P

H NMR (CDCl 3 300 MHz) δ: 0.79 (s, 3H), 0.80-0.84 (m, 6H), 0.89-0.93 (m, 6H), 2.78 –
P

R

R

2.81 (m, 2H), 3.11 (dd J = 7, 3 Hz, 2H), 3.26 (d, J = 7 Hz, 1H), 3.55 (dd, J = 10.7, 2.7
Hz, 1H), 3.75-3.86 (m, 4H), 4.39 – 4.57 (m, 6H), 5.13 (d, J = 5 Hz, 2H), 5.45 - 5.50 (m,
1H), 5.61 – 5.70 (m, 1H), 5.56 (d, J = 2.5, Hz, 1 H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H), 6.76
(d, J = 8.5 Hz, 2H), 7.02 (d, J = 8.5 Hz, 2H), 7.11 (d, J = 8.5 Hz, 2H), 7.22 (d, J = 8.5
Hz, 1H), 7.35 (s, 4H), 7.46 (d, J = 7.8 Hz, 1H), 7.51 (d, J = 6.6 Hz, 1H). MS (MALDI,
DHB) m/z 1219 (M+H, calcd for C 68 H 95 N 7 O 13 requires 1217.70)
R

R

R

R

R

R

R

R

K-2: To obtain K-2 an additional deprotection step was required to remove the benzyl
protecting group from isoleucine. K-1, (16.6 mg, 0.0125 mmol) was dissolved in EtOAc
and MeOH 1:1 ratio (2 ml) and to this was added 15% palladium on charcoal. Hydrogen
was bubbled through the reaction mixture for 20 mins. The mixture was filtered through
35

celite, concentrated under reduced pressure and dried under high vacuum to yield 16 mg
of product, white solid. Product from hydrogenolysis (16 mg, 0.013 mmol) was dissolved
in THF and TBAF in THF (0.039μl) was added. The mixture was stirred at room
temperature for 20 mins. Column chromatography was performed using CH 2 Cl 2 : MeOH
R

R

R

R

(95:5) initially and then increasing MeOH concentrations to isolate K-2 (14.0 mg, 89%)
as a yellow solid. MS (MALDI, DHB) m/z 1131 (M+H, calcd for C 61 H 91 N 7 O 13 requires
R

R

R

R

R

R

R

R

1129.67)

Figure 3.3: Mass spectrum for K-2

3.4 C-7α PROTACs syntheses /optimization of linker length
U

Our initial results from the screening done with the C-16 PROTACs indicated that
the C-16 PROTAC was not better at degrading the ER than the original E2-penta
36

PROTAC (Figure 3.4). Another observation from Figure 3.4 was that the K-1 PROTAC,
having the benzyl group was more effective in degrading the ER than K-2 lacking the
benzyl protection group. Therefore, with the belief that benzyl protection may play a role
in the activity of the PROTAC, the O-17/E2-penta was re-synthesized to include the
benzyl protecting group. All four compounds were analyzed for their ability to degrade
the ER. As displayed in Figure 3.5, the benzyl protected PROTACs showed a greater
ability to degrade the ER than unprotected PROTACs. However, the O-17 PROTACs
induced more ER degradation than any of the C-16α PROTACs.

Figure 3.4 Evaluation of C-16 and O-17 PROTACs on ER degradation. MCF-7 cells
were treated with PROTACs at the indicated concentrations (μM) or with DMSO for
48hrs. Cells were then lysed and analyzed via western blot using anti ERα antibody. βactin was used as a loading control. P-OH (E2-penta/O-17 PROTAC), K-1 and K-2
(benzyl protected and deprotected C-16 PROTACs, respectively).
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Figure 3.5 Comparisons of C-16α and O-17/E2- Penta PROTACs. MCF-7 cells were
treated with PROTACs at the indicated concentrations or with DMSO, E2 (10 nM) and
tamoxifen (TAM 5 μM) for 48hrs. Cells were lysed and analyzed via western blot using
anti ERα antibody. The intensities of the bands were quantified (%) using volumetric
densitometry (Quantity One, Bio-Rad). The ERα values were normalized to β-actin and
DMSO was arbitrarily assigned a value of 100% for comparison purposes. The benzyl
protected PROTACs were better at degrading the ER than unprotected. K-1 (C-16
PROTAC- protected C-terminus), K-2 (C-16 PROTAC - unprotected C-terminus), P-bzl
(E2-penta/O-17 PROTAC- benzyl protected C-terminus), P-OH (E2-penta/O-17
PROTAC - unprotected C-terminus).
These results indicated that the C-16 position on E2 may not be ideal for the
development of PROTACs, and as such a more appropriate derivatization site on E2 was
sought. It has been shown that derivatization at the C-7α position on estradiol results in
the maintenance of high ER-E2 binding affinity. For example, the ER antagonist
ICI182,780 which has demonstrated high binding affinity for the ER is a C-7α derivative
P

[185, 186, 187, 188]

. Based on the above data, the C-7α position on E2 was explored as a
P

possible location for further optimization of the PROTAC. The initial assessment of the
C-16 PROTACs also indicated a possible role for benzyl protection at the C-terminus of
the penatpeptide; therefore, the C-7 PROTACs contained a benzyl group at the Cterminus of the pentapeptide as well.
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Synthesis of C-7 PROTACs handle (free NH 2 )
U

UR

R

As was the case for the C-16 derivatives the first step in designing C-7α based
PROTACs was the synthesis of a short primary amine “handle” attached at the C-7α
position on estradiol which will be further extended to produce PROTACs of varying
lengths. The procedures that were used to synthesize the C-7α handle were similar to that
previously reported

[189, 190, 191, 192]
P

.
P

Scheme 3.3 Synthesis of C-7 PROTAC’s “handle” (free amine)
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Reaction details and NMR and MS data for the synthesis of C-7 PROTACs free -amine
U

handle
Compound 2: Estradiol, (8.00 g, 29.4 mmol) was dissolved in CH 2 Cl 2 (100 ml) and pR

R

R

R

R

R

toluene sulfonic acid (TsOH), (56 mg, 0.29 mmol) was added, followed by Dihydropyran
(DHP) (13.3 ml, 146.8 mmol) The mixture was stirred at room temperature, after 2 hours
water was added and product was extracted with ether. Column chromatography was
performed to isolate THP protected products as a clear oil (12 g, 94%).
1

H NMR (CDCl 3 , 500 MHz): δ 0.79, 0.81 (2s, 3H), 2.83-2.87 (m, 2H), 3.47-3.52 (m,

P

P

R

R

1H), 3.57-3.61 (m, 1H), 3.72 (t, J = 8.5 Hz, 1H), 3.89-3.97 (m, 2H), 4.64 - 4.65 (m, 1H),
5.38 - 5.39 (m, 1H), 6.78 (d, J = 2.5 Hz, 1H), 6.84 (dd, J = 8.5, 2.5 Hz, 1H), 7.22 (d, J = 8
Hz, 1H)
Compound 3: To a -78 °C solution of 2.5 M n-butyl lithium (n-BuLi) in hexanes, (30
mL, 75.0 mmol) dissolved in THF (50 mL), was added diisopropylamine (10.5 mL, 75.0
mmol), followed by 1 M potassium t-butoxide (KOt-Bu), (75.0 mL, 75.0 mmol) (a
yellow color change was observed with addition of KOt-Bu). After 5 min, a solution of
(2), (4.18 g, 9.49 mmol) dissolved in THF (20 mL) was added resulting in a dark red
color reaction mixture which was stirred for 1.5 hours at -78 °C under N 2 . The dry
R

R

ice/acetone bath was replaced with an ice bath and trimethylborate (B(OCH 3 ) 3 ) (20 mL,
R

R

R

R

171.0 mmol) was slowly added. The reaction was stirred for an additional 2 hours at 0° C
(reaction became turbid upon adition of (B(OCH 3 ) 3 ) ). 35% hydrogen peroxide (H 2 O 2 )
R

R

R

R

R

R

R

R

(25 mL) was then added and the reaction was stirred for 1 hour at room temperature, after
which time it was cooled to 0 °C, and 10% sodium thiosulfate (Na 2 S 2 O 3 ) (100 mL) was
R

R

R

R

R

R

added. Product was extracted using EtOAc, dried over Na 2 SO 4 and solvents were
R

R

R

R

ecaporated. The crude mixture was dissolved in CH 2 Cl 2 and flash chromatography was
R

R

R

R

performed (3:1, Hex:EtOAc) to afford the 6-OH compound as a pale yellow foam (2.86
g, 66% ).
P

1

H NMR (CDCl 3 , 500 MHz): δ 0.79, 0.81 (2s, 3H), 3.45-3.49 (m, 1H), 3.56 - 3.59 (m,
P

R

R

1H), 3.68 – 3.73 (m, 1H), 3.87-3.93 (m, 2H), 4.63 - 4.67 (m, 1H), 4.78 – 4.81 (m, 1H),
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5.40 - 5.43 (m, 1H), 6.92 (2dd, J = 8.5, 2.5 Hz, 1H), 7.17, 7.18 (2d, J = 8 Hz, 1H), 7.26
(d, J = 2.5 Hz, 1H).
Compound 4: The 6-OH compound, (2.86 g, 6.26 mmol) was dissolved in CH 2 Cl 2 (30
R

R

R

R

mL) and cooled to 0 °C, pyridinium chlorochromate (PCC) (2.7 g, 12.5 mmol) was then
added in portions within 15 min. After stirring for 15 min at 0 °C, the mixture was
warmed to room temperature and stirred for an additional 2 hours. The reaction was
diluted with ether (50 mL) and then filtered through Florisil to remove the chromium
salts. The solvent was evaporated and the residue was purified via flash chromatography
(3:1, Hex: EtOAc) to yield (4) as a white foam (2.28 g, 80%).
P

1

H NMR (CDCl 3 , 500 MHz): δ 0.81, 0.82 (2s, 3H), 2.73 (dd, J = 16.5, 3.5 Hz, 1H), 3.47
P

R

R

– 3.52 (m, 1H), 3.58 – 3.62 (m, 1H), 3.73, 3.75 (2t, J = 8.5 Hz, 1H), 3.86-3.94 (m, 2H),
4.63 - 4.69 (m, 1H), 5.46 – 5.48 (m, 1H), 7.21 – 7.26 (2dd, J = 8.5, 3 Hz, 1H), 7.33, 7.34
(2d, J = 8.5 Hz, 1H), 7.71, 7.72 (2d, J = 3 Hz, 1H).
Compound 5: The Ketone, (4), (1.91 g, 4.20 mmol) was dissolved in THF and cooled to
0° C, then 1M KOt-Bu (4.6 ml, 4.60 mmol) was added and mixture was stirred at 0 °C
for 30 min and then cooled to -78°C. Allyl iodide (383 μL, 4.60 mmol) was then added
(drop-wise) to the solution and after 10 min the reaction was quenched with water and
warmed to room temperature. The solvents were removed, redissolved in ether, and then
passed through a plug of silica (7-β product). After evaporation of solvents, the residue
(7-β product) was dissolved in MeOH (25 mL), and to this was added several small
pieces of sodium. The mixture was stirred for an additional 2 hours at room temperature,
then quenched with water, the MeOH was evaporated, and the product was extracted
from with ether. The solvents were evaporated and the residue was purified by flash
chromatography (5:1 Hex:EtOAc) to give (5), the 7-α product as a white foam (272 mg,
13%), recovered (4) 896 mg, corrected yield 25%. (7-α product- confirmed by NOESY,
diagonistic NOE between H 7 and H 8 ). This process was repeated two more times with
R

R

R

R

recovered starting material to provide a total (575 mg, overall uncorrected 28%, corrected
36%).
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1
P

H NMR (CDCl 3 , 500 MHz): δ 0.80, 0.82 (2s, 3H), 3.47 – 3.52 (m, 1H), 3.60 – 3.62 (m,
P

R

R

1H), 3.74, 3.77 (2t, J = 8.5 Hz, 1H), 3.87-3.94 (m, 2H), 4.63 - 4.69 (m, 1H), 4.92 – 5.00
(m, 1H), 5.45 – 5.48 (m, 1H), 5.74 – 5.82 (m, 1H), 7.22 (2dd, J = 8.5, 2.5 Hz, 1H), 7.32,
7.34 (2d, J = 8.5 Hz, 1H), 7.69 (d, J = 2 Hz, 1H).
Assignment of 7α-sterochemistry to compound (5) by NOESY 2D NMR (scanned image).

NOE7-8

H8
H7

O THP

NOE7-8

H9

THP

O

6

H8

O H7

compound (5)

Compound 6: Triethylsilane (Et 3 SiH), (4.37 ml) was added to a solution of (5) (205 mg,
R

R

0.41 mmol) in CH 2 Cl 2 and the mixture was cooled to 0 °C. Boron trifluoride
R

R

R

R

diethyletherate (BF 3 .Et 2 O) (15 ml) was added (drop-wise) and the mixture was warmed
R

R

R

R
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to room temp and stirred overnight (greenish-yellow color change). Reaction mixture was
then carefully hydrolyzed with 10% K 2 CO 3 (72 ml) and filtered through a buccner
R

R

R

R

funnel. The filtrate was extracted with CH 2 Cl 2 , dried over Na 2 SO 4 and flash
R

R

R

R

R

R

R

R

chromatography was performed (1:1, Hex:EtOAc) to yield a white solid (116 mg, 90%).
1

H NMR (CDCl 3 , 500 MHz): δ 0.79 (s, 3H), 2.72 (d, J = 16 Hz, 1H), 2.83 (dd, J = 17,

P

P

R

R

5.5 Hz, 1H), 3.77 (t, J = 8.5 Hz, 1H), 4.91 - 5.00 (m, 1H), 5.74 – 5.82 (m, 1H), 6.54 (d, J
= 3 Hz, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.15 (d, J = 8.5 Hz, 1H).
Compound 7: Imidazole, (303 mg, 4.45 mmol) was dissolved in CH 2 Cl 2 and DMF (10
R

R

R

R

ml and 2 mL respectively) and was cooled to 0 °C for about ten mins. TBDMSCl (335
mg, 2.23 mmol) was then added and the mixture was warmed to room temperature. A
solution of (6), (116 mg, 0.37 mmol in 3 ml DMF) was added to the mixture and stirred
overnight at room temeprature. CH 2 Cl 2 and DMF was evaporated and 0.1% K 2 CO 3 (30
R

R

R

R

R

R

R

R

mL) was added. The crude product was extracted with CH 2 Cl 2 and passed through a
R

R

R

R

short column (3:1 Hex:EtOAc) to yield (7) as a yellow oil (170 mg, 85%).
1

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.18 (s, 6 H), 0.75 (s, 3H), 0.89

P

P

R

R

(s, 9H), 0.97 (s, 9H), 2.70 (d, J = 16 Hz, 1H), 2.83 (dd, J = 17, 5.5 Hz, 1H), 3.65 (t, J =
8.5 Hz, 1H), 4.88 – 4.98 (m, 1H), 5.74 – 5.82 (m, 1H), 6.52 (d, J = 2.5 Hz, 1H), 6.61 (dd,
J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H).
Compound 8: A 0.5 M solution of 9-boro-bicyclononane (9-BBN) in THF (3.14 mL,
1.57 mmol) was added to a solution of steroid (7) (170 mg, 0.31 mmol) already dissolved
in THF (10 mL). After stirring overnight at room temperature the reaction was cooled to
0 °C and quenched with 3 M potassium hydroxide (KOH), (2 mL), after 5 min 35%
H 2 O 2 (2 mL) was added and the reaction was stirred for an addidional 3 h. Saturated
R

R

R

R

NaHCO3 was added and the mixture was extracted with CH 2 Cl 2 . The residue was
R

R

R

R

purified by flash chromatography (5:1 Hex:EtOAc) to provide (8) as a viscous oil (116
mg, 66%).
P

1

H NMR (CDCl 3 , 300 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.19 (s, 6 H), 0.74 (s, 3H), 0.89
P

R

R

(s, 9H), 0.97 (s, 9H), 2.68 (d, J = 16 Hz, 1H), 2.88 (dd, J = 16.7, 5.5 Hz, 1H), 3.58 – 3.60
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(m, 2H), 3.65 (t, J = 8.5 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.61 (dd, J = 8.5, 2.5 Hz, 1H),
7.11 (d, J = 8.5 Hz, 1H).
Compound 9: To a cooled solution (0 °C) of triphenyl phosphine (PPh3) (97 mg, 0.415
mmol) and THF (5 mL), was added Diisopropyl azo-dicarboxylate (DIAD) (dropwise)
(77 μl, 0.415 mmol). A white precipitate of the ylide was observed, and the reaction was
stirred for 40 min at 0 °C. A solution of (8), (116 mg, 0.207 mmol) and phthalimide (58
mg, 0.415 mmol) in THF (2 mL) was then added to the ylide. The reaction was stirred for
1 h at 0 °C and then at room temperature overnight. The solvent was evaporated in vacuo,
and the residue was purified via flash chromatography (5:1 Hex:EtOAc) to give (9) as a
white foam (118 mg, 83%).
1
P

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.18 (s, 6 H), 0.74 (s, 3H), 0.89

P

R

R

(s, 9H), 0.99 (s, 9H), 2.67 (d, J = 16.5 Hz, 1H), 2.87 (dd, J = 17, 5 Hz, 1H), 3.55 – 3.68
(m, 3H), 6.52 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H),
7.69 – 7.72 (m, 2H), 7.81 – 7.83 (m, 2H).
Compound 10: Anhydrous hydrazine (800 μl) was added to a solution of (9), (118 mg,
0.171 mmol) dissolved in DME (1.6 mL) and ethanol (1.6 mL). The mixture was refluxed
for 2 h, during which time a slightly brown precipitate formed on the sides of the flask
and the solution turned slightly green. The reaction was cooled, and 5% NaOH (1.6 mL)
was added, dissolving the precipitate. After 30 min, water was added, and the solution
was extracted with CH 2 Cl 2 , dried over Na 2 SO 4 . The solvent was evaporated in vacuo,
R

R

R

R

R

R

R

R

and the residue was purified via flash chromatography (95:5, CH 2 Cl 2 : MeOH) to give 10
R

R

R

R

as a white foam solid (56.7 mg, 76%). The TBDMS group at the 3-OH position is lost
during this reaction.
1
P

H NMR (CDCl 3 , 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.68
P

R

R

(d, J = 16.5 Hz, 1H), 2.88 (dd, J = 17, 5 Hz, 1H), 3.65 (t, J = 8.5 Hz, 1H), 6.50 (d, J = 2.5
Hz, 1H), 6.59 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H)
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Optimization of linker length of C-7 PROTACs
U

Successful synthesis of the free amine handle at the C-7α position allowed us to
vary the linker length via amide bond formation. To this end, we prepared PROTACs
with varying linker lengths. In addition, two other PROTACs, one lacking the critical
hydroxyl-proline residue (NC) and another attached at the C-terminal of the HIF-1α
derived pentapeptide (KC-6), were prepared. The schemes and detailed reaction
conditions for the synthesis of C-7 PROTACs are outlined below:
Scheme 3.4 Synthesis of KC-1 (9-atom linker)
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Synthesis of KC-1
U

Compound 11: Disuccinimidyl gluterate DSG (54 mg, 0.166 mmol) was added to the
free amine “handle”, (10), (37 mg, 0.083 mmol) and dissolved in DMF (2 ml). The
mixture was stirred at room temp overnight. DMF was removed via high vacuum and
column chromatography was performed (95:5, CH 2 Cl 2 : MeOH) to give the product as a
R

R

R

R

white solid (25 mg, 46%). For this reaction two products were isolated having similar
mobility on TLC. The upper product which was later identified by NMR to be the correct
product was reactive while the other product was unreactive in subsequent reactions.
1

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.52

P

P

R

R

(t, J = 7 Hz, 2H), 2.63 (d, J = 16.5 Hz, 1H), 2.83 (s, 4H), 3.18 – 3.26 (m, 2H), 3.65 (t, J =
8.5 Hz, 1H), 5.92 (t, J = 5.5 Hz, 1H), 6.50 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz,
1H), 7.11 (d, J = 8.5 Hz, 1H).
Compound 12: Pentapeptide-1 (24 mg, 0.009 mmol) was added to (11), (34 mg, 0.009
mmol) and then dissolved in DMF (1.5 ml). The reaction was stirred at room temp
overnight. Solvent was removed in vacuo and column chromatography was performed
(95:5 CH 2 Cl 2 : MeOH) to yield (12) as a white solid (34 mg, 70%).
R

1
P

R

R

R

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.77 – 0.85 (m,
P

R

R

6H), 0.87 – 0.94 (m, 6H), 0.89 (s, 9H), 1.30 (s, 9H), 2.63 (d, J = 16 Hz, 1H), 2.77 (s, 1H),
2.83 (dd, J = 17, 4.5 Hz, 1H), 2.93 – 3.10 (m, 3H), 3.57 (m, 1H), 3.64 (t, J = 8.5 Hz, 1H),
3.75 (d, J = 11 Hz, 1H), 4.36 – 4.67 (m, 6H), 5.11 (s, 2H), 6.53 (d, J = 2.5 Hz, 1H), 6.62
(dd, J = 8.5, 2.5 Hz, 1H), 6.74 (t, J = 5.5 Hz, 1H), 6.84 (d, J = 8 Hz, 2H), 7.04 (d, J = 8.5
Hz, 2H), 7.09 (d, J = 8.5 Hz, 1H), 7.16 (d, J = 7.5 Hz, 1H), 7.28 – 7.33 (m, 4H), 7.55 (d,
J = 7.5 Hz, 1H), 7.59 (d, J = 7 Hz, 1H).
KC-1: t-Butyl from Tyr-OH and TBDMS protecting group at the O-17 position was
simultaneously removed from (12), (34 mg, 0.027 mmol) using neat TFA (2 ml) and
R

R

stirring at room temperature until starting material disappeared ~30 min. After removal of
TFA via high vacuum, column chromatography was performed using (95:5, CH 2 Cl 2 :
R

MeOH) initially, then MeOH to isolate KC-1 as a white solid (13.8 mg, 47%).
46

R

R

R

P

1

H NMR (CDCl 3 , 500 MHz): δ 0.75 (s, 3H), 0.82 – 0.96 (m, 12H), 2.63 (d, J = 17 Hz,
P

R

R

1H), 3.19 (m, 1H), 3.49 (m, 1H), 3.57 (m, 1H), 3.68 (t, J = 8.5 Hz, 1H), 4.32 – 4.38 (m,
2H), 4.49 – 4.55 (m, 4H), 5.12 (s, 2H), 6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5
Hz, 1H), 6.72 (d, J = 8.5 Hz, 2H), 7.00 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz, 1H), 7.28
(d, J = 8 Hz, 1H), 7.31 – 7.34 (m, 4H), 7.51 (d, J = 7 Hz, 1H), 7.71 (2d, J = 7 Hz, 2H).
MS (MALDI, DHB) m/z 1130 (M+Na+, calcd for C 62 H 86 N 6 O 12 requires 1129.63)
P

P

R

Figure 3.6: Mass spectrum for KC-1
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R

R

R

R

R

R

R

Scheme 3.5 Synthesis of KC-2 (12 atom linker)

Synthesis of KC-2
U

Compound 13: Disuccinimidyl suberate (DSS), (12 mg, 0.033 mmol), was added to free
amine “handle”, (10), (14.6 mg, 0.033 mmol) and dissolved then dissolved in DMF
(1ml). The mixture was stirred at room temp overnight. DMF was removed via high
vacuum and column was performed (95:5 CH 2 Cl 2 : MeOH) to give a white solid (5.7 mg,
R

R

R

R

25%). For this reaction two products were isolated having similar mobility on TLC. The
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upper product which was later identified by NMR to be the correct product was reactive
while the other isomer was unreactive in subsequent reactions.
1

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.12

P

P

R

R

(t, J = 7.5 Hz, 2H), 2.58 (t, J = 7.5 Hz, 2H), 2.65 (d, J = 16.5 Hz, 1H), 2.82 – 2.87 (m,
5H), 3.08 – 3.12 (m, 1H), 3.24 – 3.29 (m, 1H), 3.65 (t, J = 8.5 Hz, 1H), 5.76 (t, J = 5.5
Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.61 (s, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J
= 8.5 Hz, 1H).
Compound 14: Pentapeptide-1, (6 mg, 0.008 mmol) was added to (13), (5.7 mg, 0.008
mmol) and dissolved in DMF (1.5 ml). The reaction was stirred at room temp overnight.
Solvent was removed in vacuo and column chromatography was performed using (95:5
CH 2 Cl 2 : MeOH) to yield (14) as a white solid (6.6 mg, 66%)
R

1

R

R

R

P

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.79 – 0.85 (m,

P

R

R

6H), 0.87 – 0.95 (m, 6H), 0.89 (s, 9H), 1.13 – 1.33 (m, 13H), 1.31 (s, 9H), 2.63 (d, J =
16.5 Hz, 1H), 2.83 (dd, J = 16.5, 4.5 Hz, 1H), 2.97 – 3.10 (m, 3H), 3.23 – 3.27 (m, 1H),
3.56 (dd, J = 11.1, 3.9 Hz, 1H), 3.64 (t, J = 8.5 Hz, 1H), 3.75 (d, J = 11 Hz, 1H), 4.47 –
4.62 (m, 6H), 5.11 (2s, 2H), 6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H), 6.66
(d, J = 8 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 2H), 7.08 (d, J = 8.5 Hz,
1H), 7.30 – 7.37 (m, 4H), 7.51 (d, J = 7 Hz, 1H).
KC-2: Trifluoroacetic acid (TFA) was used to remove both protecting groups (TBDMS
and t-Bu). Neat TFA was added to (14), (6.6 mg, 0.005 mmol), and the mixture was
stirred at room temperature until starting material disappeared, (45 min) observed on
TLC. Column chromatography was performed using (95:5, CH 2 Cl 2 : MeOH) initially,
R

R

R

R

then column was flushed with MeOH to isolate KC-2 as a white solid (2.5 mg, 42%).
1
P

H NMR (CDCl 3 , 300 MHz): δ 0.74 (s, 3H), 0.79 – 0.85 (m, 6H), 0.87 – 0.95 (m, 6H),
P

R

R

2.63 (d, J = 16.5 Hz, 1H), 2.83 (dd, J = 16.5, 4.5 Hz, 1H), 2.97 – 3.10 (m, 3H), 3.23 –
3.27 (m, 1H), 3.53 (dd, J = 11.1, 3.9 Hz, 1H), 3.64 (t, J = 8.5 Hz, 1H), 3.75 (d, J = 11 Hz,
1H), 4.36 – 4.54 (m, 6H), 5.14 (s , 2H), 6.53 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5
Hz, 1H), 6.74 (d, J = 8 Hz, 1H), 7.02 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 1H), 7.25
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(d, J = 8 Hz, 1H), 7.38 (s, 4H), 7.48 (d, J = 7.5 Hz, 1H), 7.54 (d, J = 7 Hz, 1H). MS
(MALDI, DHB) m/z 1172 (M+Na+, calcd for C 65 H 92 N 6 O 12 requires 1171.68)
P

P

R

Figure 3.7: Mass spectrum for KC-2

50

R

R

R

R

R

R

R

Scheme 3.6 Synthesis of KC-3 (16 atom linker)

Synthesis of KC-3
U

Compound 15: Fmoc-6-aminohexanoic acid (6-Ahx-OH/caproic acid) (13.4 mg, 0.038
mmol) was added to free amine “handle” (10), (17 mg, 0.038 mmol) and dissolved in
CH 2 Cl 2 . HBTU (21.6 mg, 0.057 mmol) and HoBt (8.73 mg, 0.057 mmol) was added to
R

R

R

R

the mixture followed by DIPEA (2 drops) The mixture was stirred at room temp until all
51

free amine was coupled (15 min-1.5 hr). Column chromatography was performed (99:1
CH 2 Cl 2 : MeOH) yielding a white foamy solid (27 mg, 91%). A small amount of diR

R

R

R

coupled product was isolated as well (5%). In some coupling reactions EDC was used as
a coupling agent instead of HBTU providing cleaner reaction (only mono-coupled)
product, but lower yields.
1

H NMR (CDCl 3 , 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.62

P

P

R

R

(d, J = 16.5 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.14 (q, J = 6.5
Hz, 2H), 3.29 – 3.34 (m, 1H), 3.64 (t, J = 8.3 Hz, 1H), 4.21 (t, J = 7 Hz, 1H), 4.41 (d, J =
7 Hz, 2H), 4.97 (t, J = 6 Hz, 1H), 5.47 (t, J = 6 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.62
(dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 7.30 – 7.33 (td, J = 7.5, 1.2 Hz, 2H),
7.40 (t, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H).
Compound 16: Fmoc-group from (15) was removed using 20% piperidine in DMF (2
ml) for 10 minutes. Following removal of solvents in vacuo, flash column
chromatography was performed using (CH 2 Cl 2 : MeOH 95:5) initially to remove by
R

R

R

R

products and finally flushing with MeOH to isolate (16) as white solid (14 mg, 73%).
1

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.60

P

P

R

R

(d, J = 16.5 Hz, 1H), 2.87 (dd, J = 16.5, 4.7 Hz 1H), 3.36 – 3.48 (m, 4H), 3.65 (t, J = 8
Hz, 1H), 5.50 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H),
7.11 (d, J = 8.5 Hz, 1H).
Compound 17: DSG (16.4 mg, 0.050 mmol) was added to (16), (14 mg, 0.025 mmol)
and dissolved in DMF (1.5 ml). The mixture was stirred at room temp for 15 min. DMF
was removed via high vacuum and column chromatography was performed using (99:1
CH 2 Cl 2 : MeOH) to remove excess DSG and then (95:5 CH 2 Cl 2 : MeOH) to give (17) as
R

R

R

R

R

R

R

R

a white solid (7 mg, 37%).
P

1

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.60
P

R

R

(d, J = 16.5 Hz, 1H), 2.31 (t, J = 7 Hz, 2H), 2.67 (t, J = 7 Hz, 2H), 2.87 ( s, 4H), 3.00 –
3.05 (m, 1H), 3.18 – 3.24 (m, 2H), 3.31 – 3.35 (m, 1H), 3.65 (t, J = 8 Hz, 1H), 5.69 (t, J
= 5.5 Hz, 1H), 6.39 (t, J = 5.5 Hz, 1H), 6.56 (d, J = 2.5 Hz, 1H), 6.64 (dd, J = 8.5, 2.5
Hz, 1H), 7.11 (d, J = 8.5 Hz, 1H).
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Compound 18: Pentapeptide-1 (10 mg, 0.013 mmol) was added to (17) (7 mg, 0.009
mmol) with catalytic amount of DMAP and then dissolved in DMF (1.5 ml). The reaction
was stirred at room temp overnight. Solvent was removed in vacuo and column
chromatography was performed (95:5 CH 2 Cl 2 : MeOH) to yield (18) as a white solid (9
R

R

R

R

mg, 74%)
1

H NMR (DMSO, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.69 (s, 3H), 0.79 - 0.86 (m,

P

P

12H), 0.87 (s, 9H), 1.25 (s, 9H), 2.58 (d, J = 16.5 Hz, 1H), 3.66 (t, J = 8 Hz, 1H), 4.22 –
4.33 (m, 4H), 4.42 (t, J = 6.7 Hz, 1H), 4.47 – 4.51 (m, 1H), 5.11 (s, 2H), 6.42 (d, J = 2.5
Hz, 1H), 6.51 (dd, J = 8.5, 2.5 Hz, 1H), 6.82 (d, J = 8.5 Hz, 2H), 7.05 (d, J = 8.5 Hz, 1H),
7.11 (d, J = 8.5 Hz, 2H), 7.36 – 7.37 (m, 4H), 7.71 (t, J = 5.5 Hz, 1H), 7.74 (t, J = 5.5
Hz, 1H), 7.82 (d, J = 8 Hz, 1H), 7.92 (d, J = 8 Hz, 1H), 8.03 (t, J = 7 Hz, 1H).
KC-3: (18), (9 mg, 0.005 mmol) was dissolved in THF (0.5 ml) and TBAF in THF (0.5
ml) was added to remove TBDMS protecting group from O-17 position. Mixture was
stirred at room temperature until starting material disappeared (48 hrs). Column
chromatography was performed using (CH 2 Cl 2 : MeOH 95:5) initially, then column was
R

R

R

R

flushed with MeOH to isolate KC-3 as a white solid (2.8 mg, 34%). In subsequent
reactions the OH on tyrosine was protected and TFA was used to remove both protecting
groups (TBDMS and t-Bu).
1
P

H NMR (DMSO, 500 MHz): δ 0.65 (s, 3H), 0.79 - 0.86 (m, 13H), 2.56 (d, J = 16.5 Hz,
P

1H), 2.75 (dd, J = 16.5, 4.5 Hz, 1H), 3.50 – 3.54 (m, 2H), 4.20 – 4.24 (m, 2H), 4.28 –
4.33 (m, 2H), 4.40 – 4.43 (m, 2H), 4.50 – 4.51 (m, 1H), 5.10 (s, 2H), 6.41 (d, J = 2.5 Hz,
1H), 6.49 (dd, J = 8.5, 2.5 Hz, 1H), 6.61 (d, J = 8.5 Hz, 2H), 6.98 (d, J = 8 Hz, 2H), 7.04
(d, J = 8.5 Hz, 1H), 7.36 (s, 4H), 7.71 (t, J = 5.5 Hz, 1H), 7.74 (t, J = 5.5 Hz, 1H), 7.77
(d, J = 8.5 Hz, 1H), 7.91 (d, J = 8 Hz, 1H), 8.00 (d, J = 8 Hz, 1H), 8.02 (d, J = 7 Hz, 1H).
MS (MALDI, CHCA) m/z 1243 (M+Na+, calcd for C 68 H 97 N 7 O 13 requires 1242.71)
P

P

R

53

R

R

R

R

R

R

R

Figure 3.8: Mass spectrum for KC-3
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Scheme 3.7 Synthesis of KC-4 (19 atom linker)

Synthesis of KC-4
U

Compound 19: Fmoc-6-aminohexanoic acid (6-Ahx-OH/caproic acid) (37 mg, 0.104
mmol) was added to the free amine “handle” (10), (46 mg, 0.104 mmol) and then
dissolved in CH 2 Cl 2 . EDC, (28 mg, 0.156 mmol) was added to the mixture followed by
R

R

R

R

DIPEA (2 drops). The mixture was stirred at room temp until all the free amine was
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coupled (15 min-1.5 hr) monitored by TLC. Column chromatography was performed
using (99:1, CH 2 Cl 2 : MeOH) to yield a white foamy solid (61 mg, 75%).
R

1

R

R

R

P

H NMR (CDCl 3 , 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.62

P

R

R

(d, J = 16.5 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.14 (q, J = 6.5
Hz, 2H), 3.29 – 3.34 (m, 1H), 3.64 (t, J = 8.3 Hz, 1H), 4.21 (t, J = 7 Hz, 1H), 4.41 (d, J =
7 Hz, 2H), 4.97 (t, J = 6 Hz, 1H), 5.47 (t, J = 6 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.62
(dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5 Hz, 1H), 7.30 – 7.33 (td, J = 7.5, 1.2 Hz, 2H),
7.40 (t, J = 7.5 Hz, 2H), 7.59 (d, J = 7.5 Hz, 2H), 7.76 (d, J = 7.5 Hz, 2H).
Compound 20: Fmoc from (19) was deprotected using 20% piperidine in DMF (3.5 ml)
for 15 minutes at room temp. Following removal of solvents in vacuo flash column
chromatography was performed using (95:5, CH 2 Cl 2 : MeOH) initially to remove byR

R

R

R

products and finally flushing with MeOH to isolate (20) as a white solid (39.5 mg, 91%).
1
P

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.60

P

R

R

(d, J = 16.5 Hz, 1H), 2.87 (dd, J = 16.5, 4.7 Hz 1H), 3.36 – 3.48 (m, 4H), 3.65 (t, J = 8
Hz, 1H), 5.50 (t, J = 5.4 Hz, 1H), 6.49 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz, 1H),
7.11 (d, J = 8.5 Hz, 1H).
Compound 21: DSS (52 mg, 0.142 mmol) was added to (20) (39.5 mg, 0.071 mmol) and
dissolved in DMF (1.5 ml). The mixture was stirred at room temp overnight. DMF was
removed via high vacuum and column was performed (99:1 CH 2 Cl 2 : MeOH) to give (21)
R

R

R

R

as a white solid (17.6 mg, 31%). Coupling confirmed by negative Kaiser test.
Compound 22: Pentapeptide-1 (16 mg, 0.022 mmol) was added to (21), (17.6 mg, 0.022
mmol) with catalytic amount of DMAP and dissolved in CH 2 Cl 2 (1.5 ml). The reaction
R

R

R

R

was stirred at room temp overnight. Solvent was removed under reduced pressure and
column chromatography was performed (95:5, CH 2 Cl 2 : MeOH) to yield (22) as a white
R

R

R

R

solid (19 mg, 61%)
1
P

H NMR (500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.80 - 0.95 (m, 12H),
P

0.89 (s, 9H), 1.31 (s, 9H), 2.63 (d, J = 16.8 Hz, 1H), 2.85 (dd, J = 16.8, 4.2, 1H), 3.06 (d,
J = 7.2 Hz, 3H), 3.13 – 3.27 (m, 4H), 3.55 (dd, J = 11.1, 3.6 Hz, 1H), 3.65 (t, J = 8 Hz,
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1H), 4.40 – 4.43 (m, 2H), 4.48 – 4.56 (m, 4H), 4.47 – 4.51 (m, 1H), 5.12, (s, 2H), 6.35 (t,
J = 5.7 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.63 (dd, J = 8.4, 2.4 Hz, 2H), 6.68 (t, J = 5.8
Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 5 Hz, 1H), 6.95 (d, J = 5.7 Hz, 1H), 7.09
(d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.34 (s, 4H).
KC-4: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat
TFA (1ml) to (22), (19 mg, 0.013 mmol) and stirring at room temperature until all
starting material disappeared (30 mim). TFA was removed in vacuo and column
chromatography was performed using (95:5 CH 2 Cl 2 : MeOH) to isolate KC-4 as a white
R

R

R

R

solid (3.6 mg, 22%). MS (MALDI, SA) m/z 1262.8 (M+H, calcd for C 71 H 103 N 7 O 13
R

requires 1261.76)

R

Figure 3.9: Mass spectrum for KC-4
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R

R

R

R

R

R

Scheme 3.8 Synthesis of KC-5 (21 atom linker)
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Synthesis of KC-5
U

Compound 23: Fmoc-caprylic acid (18 mg, 0.047 mmol) was added to the free amine
“handle” (10), (21 mg, 0.047 mmol) already dissolved in CH 2 Cl 2 . EDC (13.5 mg, 0.070
R

R

R

R

mmol) was added to the mixture followed by DIPEA (2 drops) and mixture was stirred at
room temp until all free amine was coupled (15 min-1.5 hr) monitored by TLC. Column
chromatography was performed, (99:1, CH 2 Cl 2 : MeOH) yielding a white foamy solid (32
R

R

R

R

mg, 84%).
1

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.60

P

P

R

R

(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.04 – 3.10 (m, 1H), 3.12 (q, J = 7.4
Hz, 2H), 3.64 (t, J = 8.3 Hz, 1H), 4.17 (t, J = 7 Hz, 1H), 4.34 (d, J = 7 Hz, 2H), 5.00 (t, J
= 6 Hz, 1H), 5.82 (t, J = 6 Hz, 1H), 6.51 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.5, 2.5 Hz,
1H), 7.06 (d, J = 8.5 Hz, 1H), 7.30 – 7.31 (td, J = 7.5, 1.0 Hz, 2H), 7.39 (t, J = 7.5 Hz,
2H), 7.56 (d, J = 7.5 Hz, 2H), 7.72 (d, J = 7.5 Hz, 2H).
Compound 24: Fmoc group from (23), (32 mg, 0.040 mmol) was removed using 20%
piperidine in DMF (2ml) for 10 minutes at room temperature. Following removal of
solvents in vacuo flash column chromatography was performed using (CH 2 Cl 2 : MeOH
R

R

R

R

95:5) initially to remove by-products and finally flushing with MeOH to isolate (24) as
white solid (13 mg, 56%). Deprotection confirmed by Kaiser test.
Compound 25: DSS (42 mg, 0.111 mmol) was added to (24) (13 mg, 0.022 mmol) and
the reagents were dissolved in DMF (2.5 ml) the mixture was stirred at room temp
overnight. DMF was removed via high vacuum and column was performed (99:1
CH 2 Cl 2 : MeOH) to give (25) as a white solid (5.8 mg, 31%).
R

P

1

R

R

R

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.60
P

R

R

(t, J = 7.2 Hz, 1H), 2.84 (s, 2H), 3.21 – 3.28 (m, 2H), 3.64 (t, J = 8.3 Hz, 1H), 5.61(t, J =
5.7 Hz, 1H), 5.87 (t, J = 5.7 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H), 6.66 (dd, J = 8.5, 2.5 Hz,
1H), 7.11 (d, J = 8.5 Hz, 1H).
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Compound 26: Pentapeptide-1 (5.2 mg, 0.007 mmol) was added to (25), (5.8 mg, 0.007
mmol) with catalytic amount of DMAP and dissolved in CH 2 Cl 2 (3 ml). The reaction
R

R

R

R

was stirred at room temp overnight. Solvent was removed under reduced pressure and
column chromatography was performed (95:5 CH 2 Cl 2 : MeOH) to yield (26) as a white
R

R

R

R

solid (4.8 mg, 48%)
1
P

H NMR (500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.80 - 0.95 (m, 12H),
P

0.89 (s, 9H), 1.31 (s, 9H), 2.63 (d, J = 16.8 Hz, 1H), 2.85 (dd, J = 16.8, 4.2, 1H), 3.06 (d,
J = 7.2 Hz, 3H), 3.13 – 3.27 (m, 4H), 3.55 (dd, J = 11.1, 3.6 Hz, 1H), 3.65 (t, J = 8 Hz,
1H), 4.40 – 4.43 (m, 2H), 4.48 – 4.56 (m, 4H), 4.47 – 4.51 (m, 1H), 5.13 (s, 2H), 6.35 (t,
J = 5.7 Hz, 1H), 6.53 (d, J = 2.4 Hz, 1H), 6.63 (dd, J = 8.4, 2.4 Hz, 2H), 6.68 (t, J = 5.8
Hz, 1H), 6.86 (d, J = 8.4 Hz, 2H), 6.92 (d, J = 5 Hz, 1H), 6.95 (d, J = 5.7 Hz, 1H), 7.09
(d, J = 8.4 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.34 (s, 4H).
KC-5: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat
TFA (1ml) to 26 (4.8 mg, 0.003 mmol) and stirring at room temperature until all starting
material disappeared (30 mim). TFA was removed in vacuo and column chromatography
was performed (CH 2 Cl 2 : MeOH 95:5) to isolate KC-5 as a white solid (0.8 mg, 19%).
R

R

R

R

MS (MALDI, SA) m/z 1312 (M+Na+, calcd for C 73 H 107 N 7 O 13 requires 1312.79)
P

P

R
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R

R

R

R

R

R

R

Figure 3.10: Mass spectrum for KC-5
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Scheme 3.9 Synthesis of KC-6 ( 12 atom linker attached at the C-terminus of HIFpentapeptide)
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Synthesis of KC-6
U

Compound 27: Fmoc-caprylic acid (29.2 mg, 0.077 mmol) was added to the free amine
“handle” (10), (34 mg, 0.077 mmol) and then dissolved in CH 2 Cl 2 . EDC (22 mg, 0.115
R

R

R

R

mmol) was added to the mixture followed by DIPEA (2 drops) and mixture was stirred at
room temp until all free amine was coupled (15 min-1.5 hr), monitored by TLC. Column
chromatography was performed (99:1, CH 2 Cl 2 : MeOH) yielding a white foamy solid (53
R

R

R

R

mg, 62%).
1

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.62

P

P

R

R

(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.06 – 3.30 (m, 4H), 3.64 (t, J = 8.3
Hz, 1H), 4.20 (t, J = 7 Hz, 1H), 4.40 (d, J = 7 Hz, 2H), 4.91 (t, J = 5.5 Hz, 1H), 5.54 (t, J
= 5.5 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.10 (d, J = 8.5
Hz, 1H), 7.32 (m, 2H), 7.39 (t, J = 7.5 Hz, 2H), 7.58 (d, J = 7.5 Hz, 2H), 7.75 (d, J = 7.5
Hz, 2H).
Compound 28: Fmoc from (27), (53 mg, 0.065 mmol) was deprotected using 20%
piperidine in DMF (3 ml) for 10 minutes at room temperature. Following removal of the
solvents in vacuo, flash column chromatography was performed using (95:5 CH 2 Cl 2 :
R

R

R

R

MeOH) initially to remove by-products and finally flushing with MeOH to isolate (28) as
white solid (30 mg, 79%).
Compound 29: Pentapeptide-3 (17 mg, 0.023 mmol) was added to (28) (13.6 mg, 0.023
mmol) and both were dissolved in DMF (1.5 ml). The reaction was stirred at room temp
overnight. Solvent was removed in vacuo and column chromatography was performed
(4:1 CH 2 Cl 2 : MeOH) to yield (29) as a white solid (17 mg, 56 %).
R

1
P

R

R

R

H NMR (CDCl 3 , 300 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.62
P

R

R

(d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5, 4.7 Hz 1H), 3.00 – 3.26 (m, 5H), 3.64 (t, J = 8.3
Hz, 1H), 4.20 – 4.25 (m, 2H), 4.22 – 4.56 (m, 3H), 5.10 (s, 2H), 6.53 (d, J = 2.5 Hz, 1H),
6.63 (dd, J = 8.5, 2.5 Hz, 1H), 6.74 (t, J = 8 Hz, 2H), 6.94 (d, J = 8 Hz, 1H), 7.00 (d, J = 8
Hz, 2H), 7.11 (d, J = 8 Hz, 1H), 7.22 (d, J = 8 Hz, 1H), 7.31(m, 2H), 7.89 (d, J = 6 Hz,
1H).
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KC-6: TBDMS protecting group was removed by adding neat TFA (1ml) to (29) (9.8
mg, 0.007 mmol) and stirring at room temperature for 30 mim. TFA was removed in
vacuo and column chromatography was performed (CH 2 Cl 2 : MeOH 95:5) to isolate KCR

R

R

R

6 as a white solid (6 mg, 67%).
P

1

H NMR (CDCl 3 , 300 MHz): 0.77 (s, 3H), 2.64 (d, J = 17 Hz, 1H), 2.85 (dd, J = 16.5,
P

R

R

4.7 Hz 1H), 3.04 – 3.20 (m, 4H), 3.67 (t, J = 8.3 Hz, 1H), 4.20 – 4.23 (m, 2H), 4.37 –
4.56 (m, 3H), 5.10 (s, 2H), 5.90 (d, J = 8 Hz, 1H), 5.96 (d, J = 8.5 Hz, 1H), 6.16 (d, J = 6
Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 6.73 (t, J = 8.5 Hz, 2H),
6.92 (d, J = 8.5 Hz, 1H), 6.98 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 8.5 Hz, 2H), 7.27 – 7.32
(m, 2H), 7.56 (d, J = 6 Hz, 1H), 7.79 (d, J = 7 Hz, 1H). MS (MALDI, CHCA) m/z 1200.7
(M+Na+, calcd for C 66 H 95 N 7 O 12 requires 1200.7)
P

P

R

R

R

R

R

R

R

R

Figure 3.11: Mass spectrum for KC-6
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Scheme 3.10 Synthesis of NC – (negative control, HyP substituted with norleucine)

Synthesis of NC – negative control
U

Compound 30: DSS, (108 mg, 0.394 mmol) was added to the free amine “handle” (10),
(35 mg, 0.079 mmol) and both were dissolved in DMF (5 ml). The mixture was stirred at
room temp overnight. DMF was removed via high vacuum and column chromatography
was performed (95:5, CH 2 Cl 2 : MeOH) to give a white solid (17 mg, 31%).
R

R

R

R

65

1

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.12

P

P

R

R

(t, J = 7.5 Hz, 2H), 2.58 (t, J = 7.5 Hz, 2H), 2.65 (d, J = 16.5 Hz, 1H), 2.82 – 2.87 (m,
5H), 3.08 – 3.12 (m, 1H), 3.24 – 3.29 (m, 1H), 3.65 (t, J = 8.5 Hz, 1H), 5.76 (t, J = 5.5
Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.61 (s, 1H), 6.64 (dd, J = 8.5, 2.5 Hz, 1H), 7.11 (d, J
= 8.5 Hz, 1H).
Compound 31: Pentapeptide-2, (8.5 mg, 0.011 mmol) was added to (30), (8 mg, 0.011
mmol) and both were dissolved in CH 2 Cl 2 (1.5 ml). The reaction was stirred at room
R

R

R

R

temp overnight. Solvent was removed under reduced pressure and column
chromatography was performed (95:5 CH 2 Cl 2 : MeOH) to yield (31) as a white solid (9.3
R

R

R

R

mg, 62%)
1
P

H NMR (CDCl 3 , 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.74 (s, 3H), 0.81 – 0.95 (m,
P

R

R

12H), 0.89 (s, 9H), 1.30 (s, 9H), 2.65 (d, J = 16.5 Hz, 1H), 2.86 (dd, J = 16.5, 4.8 Hz,
1H), 2.92 (d, J = 6 Hz, 1H), 2.06 – 3.13 (m, 2H), 3.20 – 3.30 (m, 1H), 3.70 – 3.46 (m,
5H), 3.66 (t, J = 8.5 Hz, 1H), 4.21 – 4.36 (m, 3H), 4.47 -4.50 (m, 1H), 4.57 – 4.64 (m,
1H), 5.13 (s , 2H), 6.47 (d, J = 4.5 Hz, 1H), 6.22 (d, J = 8.5 Hz, 1H), 6.50 (dd, J = 8.5,
2.5 Hz, 1H), 6.85 (d, J = 8.5 Hz, 2H), 7.10 (d, J = 8.5 Hz, 2H), 7.12 (d, J = 8.5 Hz, 1H),
7.22 (d, J = 7.5 Hz, 1H), 7.26 (d, J = 8.5 Hz, 1H), 7.35 (s, 4H), 7.44 (d, J = 7.5 Hz, 1H),
7.57 (d, J = 8.5 Hz, 1H), 7.63 (d, J = 6 Hz, 1H).
NC: TBDMS and t-Bu protecting groups were removed simultaneously by adding neat
TFA (1ml) to (31) (9.3 mg, 0.007 mmol) and stirring at room temperature for 30 min.
TFA was removed in vacuo and column chromatography was performed (95:5, CH 2 Cl 2 :
R

MeOH) to isolate NC as a white solid (2.9 mg, 36%).
MS (MALDI, SA) m/z 1149.8 (M+H, calcd for C 65 H 92 N 6 O 12 requires 1149.68)
R

66

R

R

R

R

R

R

R

R

R

R

Figure 3.12: Mass spectrum for NC

M+H

3.5 Synthesis of KC-7/Dimeric ligand PROTAC
Based on the fact that a number of proteins exist as dimers, (including the ER,
which dimerizes upon E2 binding) attempts have been made to produce dimeric
compounds that can interact with both members of such dimers [193, 194, 195]. It is thought
P

P

that dimeric ligands that are suitably engineered, having a proper spacer between the two
ligands, for example, should produce higher selectivity and potency when compared to
their monomeric counterparts [194].
P

P

As such the synthesis of dimeric ligands as: anti-cancer agents, example,
geldanamycin dimer targeting Hsp90 and HER2
benzamides (DIBAs) dimers,

[196]
P

P

; anti-HIV agents example disulfide

that were found to selectively target the HIV-

1nucleocapsid protein zinc (NCp7 Zn) fingers [197]. Dimeric ER lignads have also been
P

67

P

synthesized from both steroidal and non steroidal ligands [195, 198, 199, 200]. Hexestrol dimers
P

P

showed some antiestrogenic activities [198] and a triphenylethylene dimer containing six
P

P

hydroxyls had similar activity to tamoxifen, but was not specific for ER positive breast
cancer cells [201]. Estrone dimers were also synthesized but, had no antiestrogenic activity
P

P

and in fact stimulated cell proliferation similar to E2 [200]. Other ER dimers were linked at
P

P

the 17-β position on E2 and showed minimal cytotoxicity in MCF-7 cells when compared
with tamoxifen, but were cytotoxic to murine skin cancer cells [195, 199].
P

P

Similar to the aforementioned studies, in an attempt to improve the efficiency of
the PROTAC, a dimeric PROTAC was synthesized. The dimeric PROTAC was linked at
the C-7α position on E2 (unlike the other ER targeting dimers previously mentioned
aboved), which we hope would retain the binding affinity for the ER. The Scheme and
reaction details for synthesis of the dimeric PROTAC are reported below.

.
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Scheme 3.11 Synthesis of KC-7/dimeric ligand PROTAC
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Scheme 3.11 Synthesis of KC-7/dimer continued

Reaction details for synthesis of KC-7/dimeric ligand PROTAC
U

Compound 2: The 3-OH deprotected compound isolated from the synthesis of (8) in
scheme 3, was re-protected with a benzyl group. K 2 CO 3 (1.2 g, 8.50 mmol) was added to
R

R

R

R

(8) (470 mg, 1.06 mmol) and contents were dissolved in DMF, benzyl bromide (BnBr)
(195 μl, 1.60 mmol) was then added and the reaction was stirred overnight at room
70

temperature. DMF was removed in vacuo and column chromatography was performed
(5:1 Hex:EtOAc) to yield (2) (454 mg, 80%).
1

H NMR (CDCl3, 500 MHz): δ 0.02 (s, 3H), 0.03 (s, 3H), 0.74 (s, 3H), 0.89 (s, 9H), 2.73

P

P

(d, J = 16.5 Hz, 1H), 2.92 (dd, J = 17, 5 Hz, 1H), 3.60 (t, J = 6.2 Hz, 2H), 3.65 (t, J = 8
Hz, 1H), 5.02 (s, 2H), 6.70 (d, J = 2.5 Hz, 1H), 6.78 (dd, J = 8.7, 2.7 Hz, 1H), 7.20 (d, J =
8.5 Hz, 1H), 7.30- 7.44 (m, 5H)
Compound 3: To a cooled solution (0 °C) of PPh3 (443 mg, 1.70 mmol) in THF (10 mL)
was added DIAD (dropwise) (332 μl, 1.70 mmol). A white precipitate of the ylide was
observed, and the reaction was stirred for 40 min at 0 °C. A solution of (2), (454 mg,
0.850 mmol) and phthalimide (249 mg, 1.70 mmol) dissolved in THF (5 mL) was then
added to the ylide. The reaction was stirred for 1 h at 0 °C and then at room temperature
overnight. The solvent was evaporated under reduced pressure and the residue was
purified via flash chromatography (5:1 Hex:EtOAc) to give (3) as a white foam (369 mg,
65%).
1
P

H NMR (CDCl3, 500 MHz): δ 0.03 (s, 3H), 0.04 (s, 3H), 0.73 (s, 3H), 0.89 (s, 9H), 2.72
P

(d, J = 17 Hz, 1H), 2.92 (dd, J = 17, 5 Hz, 1H), 3.60 (t, J = 6.2 Hz, 2H), 3.65 (t, J = 8 Hz,
1H), 5.01 (s, 2H), 6.70 (d, J = 2.5 Hz, 1H), 6.76 (dd, J = 8.7, 2.7 Hz, 1H), 7.20 (d, J = 8.5
Hz, 1H), 7.30- 7.44 (m, 5H), 7.69- 7.71 (m, 2H), 7.82- 7.83 (m, 2H)
Compound 4: Three different deprotection reactions were performed to give (4). (i)
deprotection of TBDMS: hydrogen fluoride (HF) (540 μl) was added to a 25 ml round
bottom flask containing (3), (172 mg, 0.260 mmol), already dissolved in THF and
CH 3 CN. The mixture was heated to approximately 60°C for 20 min. After cooling, the
R

R

mixture was quenched with saturated NaHCO 3 and then solid NaHCO 3 until neutral, then
R

R

R

R

extracted with CH 2 Cl 2 . After drying over Na 2 SO 4 the solvent was evaporated under
R

R

R

R

R

R

R

R

reduced pressure and the residue was purified via flash chromatography (5:1 Hex:EtOAc)
(134 mg). (ii) release of free amine: Product (134 mg, 0.244 mmol) obtained from (i)
above was dissolved in equal amounts of DME and EtOH (5 ml and 5 ml) and hydrazine
(163 μl) was added and the mixture was refluxed for 2 h, during which time slightly
brown precipitate formed on the sides and the solution turned slightly green. The reaction
71

was cooled, and 5% NaOH was added, dissolving the precipitate. After 30 min, water
was added, and the solution was extracted with CH 2 Cl 2 , dried over Na 2 SO 4 and the
R

R

R

R

R

R

R

R

solvent was evaporated in vacuo. The residue was purified via flash chromatography
(95:5, CH 2 Cl 2 : MeOH) to give the amine as a white foam solid (79 mg). (iii)
R

R

R

R

hydrogenolysis: The amine from (ii) (79 mg) was dissolved in 1:1 EtOAc: MeOH and
10% palladium on charcoal (Pd-C) (12 mg) was added, hydrogen was bubbled through
the mixture and the reaction was monitored by TLC until all starting material
disappeared. Mixture was filtered through celite and solvent was evaporated to yield (4)
as a white solid (58 mg, 96%).
1

H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H), 2.67 (d, J = 17 Hz, 1H), 2.88 (dd, J = 17, 5

P

P

Hz, 1H), 3.70 (t, J = 8 Hz, 1H), 6.54 (d, J = 2.3 Hz, 1H), 6.63 (dd, J = 8.5, 2.3 Hz, 1H),
7.11 (d, J = 8.5 Hz, 1H)

Compound 5: Fmoc-caprylic acid (28.6 mg, 0.075 mmol) was added to (4), (24.7 mg,
0.075 mmol) dissolved in CH 2 Cl 2 and DMF. HBTU (43 mg, 0.112 mmol) and was added
R

R

R

R

to the mixture followed by DIPEA (2 drops) and mixture was stirred at room temp for 30
min. solvents were removed in vaccuo and the residue was purified by column
chromatography (CH 2 Cl 2 : MeOH 95:5) yielding a white foamy solid (17.5 mg, 34%).
R

R

R

R

Fmoc from the product above (ii) (17.5 mg, 0.075 mmol) was deprotected using 20%
piperidine in DMF. After solvent removal the residue was purified via flash column
chromatography (CH 2 Cl 2 : MeOH 95:5) to yield (5), (11 mg, 92%).
R

R

R

R

Amine was

confirmed using Kaiser test.
Compound 6: Pentapeptide-3 (18 mg, 0.023 mmol) and DMAP was added to (5) (11
mg, 0.023 mmol) and the contents were dissolved in DMF (2.5 ml). The reaction was
stirred at room temp overnight. The solvents were removed in vacuo and column
chromatography was performed (4:1 CH 2 Cl 2 : MeOH) to yield (6) as a white solid (17
R

R

R

R

mg, 63 %)
1
P

H NMR (CDCl3, 500 MHz): δ 0.66 (s, 3H), 0.67 – 0.87 (m, 16H), 2.57 (d, J = 16.5 Hz,
P

1H), 2.72 – 2.80 (m, 2H), 2.94 – 2.99 (m, 4H), 3.45 – 3.57 (m, 3H), 4.04 – 4.23 (m, 2H),
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4.28 – 4.49 (m, 4H), 4.51 (d, J = 5 Hz, 1H), ( )5.02 (s, 2H), 6.41 (d, J = 2.5 Hz, 1H), 6.50
(dd, J = 8.5, 2.5 Hz, 1H), 6.60 – 6.63 (m, 2H), 6.97 – 7.01 (m, 2H), 7.05 (d, J = 8.5 Hz,
1H), 7.29 - 7.46 (m, 5H), 7.65 (d, J = 9.5 Hz, 1H), 7.82- 7.83 (m, 2H), 7.86 (d, J = 8 Hz,
1H), 8.00 (d, J = 7 Hz, 1H), 8.06 (d, J = 7 Hz, 1H), 8.19 (d, J = 6 Hz, 1H)
Compound 7: (6), (17 mg, 0.015 mmol) was dissolved in 1:1 EtOAc: MeOH, Pd-C was
added and hydrogen was bubbled through the mixture for 1hr. The mixture was filtered
through celite and solvent evaporated to give (7) as a pale yellow solid (15 mg, 98%).
Free amine confirmed by Kaiser test.
Compound 8: DSS (15 mg, 0.042 mmol) was added to (7) (15 mg, 0.014 mmol) and
dissolved in DMF (0.5 ml) the mixture was stirred at room temp overnight. DMF was
removed via high vacuum and column chromatography was performed (95:5 CH 2 Cl 2 :
R

R

R

R

MeOH) to give (8) as a yellow solid (5.5 mg, 31%).
1
P

H NMR (CDCl3, 500 MHz): δ 0.77 (s, 3H), 0.80 – 1.01 (m, 10 H), 1.02 (t, J = 6.5 Hz,
P

3H), 2.30 (t, J = 7.5 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 3.02 – 3.24 (m, 5H), 3.47 – 3.54
(m, 1H), 3.63 – 3.72 (m, 3H), 4.17 – 4.27 (m, 1H), 4.43 – 4.54 (m, 4H), 6.36 (t, J = 6 Hz,
1H), 6.40 (t, J = 6 Hz, 1H), 6.53 (d, J = 2.5 Hz, 1H), 6.63 (dd, J = 8.5, 2.5 Hz, 1H), 6.75
(t, J = 8.5 Hz, 2H), 6.95 (d, J = 8 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 8.5Hz,
1H), 7.14 (d, J = 4.5 Hz, 1H), 7.16(d, J = 4.5 Hz, 1H), 7.26 (d, J = 7Hz, 1H), 7.58 (t, J =
6 Hz, 1H), 7.73 (t, J = 6 Hz, 1H),
Compound 9: (8), (5.5 mg, 0.004 mmol), (4) (3 mg, 0.009 mmol) and DMAP was
dissolved in DMF and mixture was stirred at room temperature overnight. Solvents were
removed in vaccuo and flash column chromatography was performed (95:5 CH 2 Cl 2 :
R

R

R

R

MeOH) to give the (KC7/dimer) as a yellow solid (4.1 mg, 68%). Mass spectrum
indicated below. MS (MALDI, SA) m/z 1534 (M+Na+, calcd for C 87 H 130 N 8 O 14 requires
P

1533.97)
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P

R

R

R

R

R

R

R

R

Figure 3.13: Mass spectrum for Dimer

3.6 Summary
Syntheses resulted in the development of ten PROTACs. Two C-16α PROTACs,
K1 and K2 were synthesized (Scheme 3.2) having a linker attached at the C-16α position
via a carbon-carbon (C-C) bond. The C-C bond was used as an alternative to the ester
bond used in the original ER-targeting PROTAC (Figure 3.1). The C-terminal benzyl
protecting group on the HIF derived pentapeptide was not removed in K-1 in order to
evaluate its potential in stabilizing the PROTAC while the benzyl group was removed
from K-2 analogous to the O-17/E2-penta PROTAC.
All other PROTACs were synthesized as C-7α PROTACs. In this series eight
PROTACs were developed. Five were developed in an attempt to optimize the linker
length, KC-1, KC-2, KC-3, KC4, and KC-5, (Scheme 3.4 to 3.8). In an effort to decipher
whether the location of attachment of the linker to the HIF pentapeptide was important, a
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PROTAC KC6 (Scheme 3.9) was also synthesized having the linker attached at the Cterminal isoleucine residue. To help validate the mechanism of PROTAC action the
critical Hyp was replaced with a nor-leucine reside. A dimeric PROTAC was also
developed in the hope of improving the PROTAC efficiency.

Copyright © Kedra C.Cyrus 2009
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CHAPTER 4: BIOLOGICAL CHARACTERIZATIONS
The data presented in this chapter were generated in collaboration with Marie
Wehenkel (western blot, immunofluorescence, rt-PCR), Hyeong- Jun Han (MTS assay),
Dr. Eun-Young Choi (binding assay) and, Dr. Wooin Lee’s lab - Eun Young Jang &
Kyungwha Kim (qrt-PCR). Thanks to the following laboratories for use of their
equipment: Dr. Tai (microplate reader), Dr. Dr. Wooin Lee (fluorescence microscope)
and Drs. Black, Graf, and Leggas (fluorescence microscope).

4.1 Introduction
PROTACs were tested in MCF-7 breast cancer cells for their ability to ER induce
degradation. MCF-7 cells were treated with PROTACs and the effect of PROTACs on
ERα protein levels was evaluated using western blot and immunofluorescence (IF). IC 50
R

was also established for all compounds. Once an optimum compound was identified it

R

was screened further for its potential effects on the ER downstream target gene, the
progesterone receptor (PR). The belief is that if ER is degraded then genes that are
normally dependent on ER for transcriptional activation will display only basal
expression levels.

4.2 Materials and Methods
Reagents:
U

The following reagents were obtained from Bio-Rad: Tris-Cl Triton X-100,
Protein Assay Dye Reagent Concentrate, Sodium Dodecyl Sulfate (SDS) 20% (w/v),
0.5M Tris-HCl Buffer pH 6.8, 1.5M Tris-HCl Buffer pH 8.8, 30% Acrylamide/Bis
Solution 29:1, Immun-Blot PVDF Membrane, Blocking Grade Non-Fat Dry Milk, and
Prestained SDS-PAGE Standards, Low Range.
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The following reagents were obtained from Sigma-Aldrich: Protease Inhibitor
Cocktail; Sample Buffer, Laemmli 2X Concentrate; Ammonium Persulfate (APS);
N,N,N',N'-Tetramethylethylenediamine (TEMED); Bovine Serum, Albumin (BSA);
Kodak GBX Developer/Replenisher; Kodak GBX Fixer/Replenisher; Kodak BioMax
XAR Film;Sodium Bicarbonate; Glycero; HEPES; Magnesium Chloride (MgCl 2 )
R

R

hexahydrate, 99%, ACS reagent; TWEEN® 20; Ethylenediaminetetraacetic acid
(EDTA); Phosphatase Inhibitor Cocktail 1; Dithiothreitol (DTT); and Sodium
Orthovanadate (Na 3 VO 4 ).
R

R

R

R

The following reagents were obtained from Gibco: Goat Serum; Fetal Bovine
Serum (FBS) heat inactivated; 10X Hanks’ Balanced Salt Solution (HBSS); PenicillinStreptomycin (P/S); RPMI Medium 1640; 10X Trypsin-EDTA (TE); and RPMI 1640
Medium phenol-red free.
Additional reagents were supplied by other companies. The Amersham ECL
Western Blotting Detection Reagents were purchased from GE Healthcare, Sodium
Chloride and Methylsulfoxide (DMSO) were purchased from EMD, Nonidet-P40 was
purchased from Fluka, PVDF membranes were purchased from Biorad, Prolong Gold
antifade w/ DAPI was purchased from Invitrogen, CellTiter 96® Aqueous One Solution
Cell Proliferation Assay was purchased from Promega, Charcoal/Dextran Treated Fetal
Bovine Serum was purchased from Hyclone, Antibody Dilutant w/ Background Reducing
Components was purchased from DAKO, Potassium Chloride (KCl) ACS Grade was
purchased from EM Science, Formaldehyde, Para (PFA), Laboratory Grade was
purchased from Fisher Scientific, Potassium Phosphate Monobasic (KH 2 PO 4 ) and
R

R

R

R

Sodium Phosphate Dibasic Heptahydrate (Na 2 HPO 4 ) were both purchased from
R

R

R

R

Mallinckrodt Baker. β-glycerolphosphate was a kind gift from Dr. Penni Black.
Antibodies:
U

The following primary antibodies were used for western blotting: Estrogen
Receptor-α (ERα), Histone deacetylase 1 (HDAC1), (Santa Cruz).

Cyclin D1,

(NeoMarkers) and β-actin (Novus Biologicals).
Secondary antibodies: Anti-Mouse IgG horseradish peroxidase (Host: Goat)
(Zymed); Anti-Rabbit IgG horseradish peroxidase (Host: Donkey), (Amersham).
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Antibodies for immunofluorescence:

Primary antibody, ERα (Abcam).

Conjugated secondary antibody Alexa Fluor 488 (FITC) goat anti-rabbit IgG
(Invitrogen). Also from Invitrogen was the f-actin stain Rhodamin Phallodin, which was
first dissolved in methanol according to the manufacturer’s instructions and then used at a
concentration of 1:1000 in PBS [R415].

Cell Culture & Treatment:
U

MCF7 cells were purchased from the American Type Culture Collection
(Manassas, VA) and maintained in RPMI 1640 Medium supplemented with 10% (v/v)
fetal bovine serum and a mixture of 100U/mL penicillin and 100µg/mL streptomycin
(P/S). Cells were grown in an incubator at 37°C with a 5% carbon dioxide atmosphere.
Media was changed to RMPI plus P/S with 5% Charcoal/Dextran-treated FBS after
washing with HBSS and at least 24 hours prior to treatment of the cells with compounds.
Cells were added to 12 or 24 well plates and treated once they reached 70% confluence.
Compounds were treated in a DMSO vehicle at the appropriate dilutions for 48 hours,
unless noted otherwise.
Western Blotting:
U

Whole cell lysates were prepared by incubating cells in nondenaturing lysis buffer
(50nM Tris-Cl, 150mM NaCl, 1% NP40, 1% Triton X-100, and 1% protease inhibitor
cocktail) on ice for 1 hour. Cells were then centrifuged at 14,000 rpm for 10 min at 4°C
(Sorvall Biofuge Primo R, Kendro Laboratory Products, Newtown, CT). Supernatants
were collected and subjected to protein assay via method of Bradford using Protein Assay
Dye Reagent Concentrate. Protein concentrations were determined by a GENESYS 10
spectrophotometer, Thermo Spectronic (VWR, Arlington Heights, IL). The supernatants
were then added 2x Laemmli Sample Buffer and heated in boiling water for 10 min.
Subsequently, the denatured whole cell lysates were resolved by 8%-12% SDS-PAGE
and transferred to PVDF membranes. Membranes were blocked with 5% skim milk or
BSA for 1 hour at room temperature on the rotator. Appropriate primary and secondary
antibodies were used to incubate the membranes for 1 hour at room temperature on the
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rotator or overnight at 4°C. Finally, Amersham ECL Western Blotting Detection
Reagents were used to visualize protein of interests on Kodak BioMax XAR Films.
Antibodies were used at the following dilutions: ERα (1:200), β-actin (1:5000), antirabbit (1:10000 or 1:5000), and anti-mouse (1:5000). Exposure: ERα (1-5 minutes), and
β-actin (5-60 seconds).

Quantification:
U

The intensities of the bands on western blot films were quantified using
volumetric densitometry (Quantity One, Bio-Rad). The estrogen receptor-alpha values
were normalized to β-actin and DMSO was arbitrarily assigned a value of 100% for
comparison purposes.
Cell Proliferation Assay:
U

Cells were seeded in a 96 well plate at a concentration of 5,000 cells per well and
allowed to attach for 24 hours. The media was changed to 5% Charcoal RPMI for 24
hours prior to the addition of compounds.

During the 48 hour treatment, ten

concentrations were tested plus one vehicle and one media control. At the end of the
treatment time, 20µL of the CellTiter 96® assay dye was added to the media in each well
and allowed to react at 37°C for one hour. Absorbance was then measured at 490nm on a
microplate reader using the KC4 data analysis program from BioTek®. In GraphPad
Prism® (San Diego, USA), IC 50 values were obtained from a sigmoid dose-response
R

R

curve using a nonlinear regression to a logarithmic function. The data represent at least
three replicates.
Immunofluorescence:
U

Coverslips were sterilized with ethanol and UV light exposure in 35mm dishes.
Cells were added directly to the dish and allowed to attach for 24 hours. The media was
then changed to phenol-red free RPMI with 5% Charcoal/Dextran-treated FBS until
treatment with compounds. Compounds were diluted in the phenol-red free media, and
treated as detailed previously.
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After treatment, cells were fixed with 4% PFA at 37°C for 7 minutes, washed
with PBS, and then permeablized with 0.2% Triton-X in PBS at 37°C for 30 minutes.
Between all subsequent steps coverslips were washed in PBST (PBS with 0.05% Tween20). Blocking in 10% goat serum with 0.1% BSA in PBST was performed at 37°C for 1
hour or 4°C overnight. Primary antibody (ERα) was added directly to the coverslip at a
concentration of 1:1000 in DAKO antibody dilutant at 37°C for one hour, then secondary
antibody (FITC) was added in the same way for 30 minutes. The f-actin stain was diluted
to 1:1000 in PBS, added directly to the coverslip, and incubated at 37°C for 30 minutes.
After extra washing, the coverslips were removed from the dishes and dried briefly.
20µL of Prolong Gold with DAPI per coverslip was added to clean slides and the
mounted slides were allowed to dry overnight. After drying, the coverslips were rimmed
with clear nail polish and visualized on a fluorescent microscope.
Competitive Ligand Binding Assay:
U

U

Competitive ligand binding assays were performed according to the
manufacturer’s protocol (Invitrogen). Purified human recombinant estrogen receptor
(approximately 10 nM) was added to a saturating amount of [3H]-labeled estradiol (20
P

P

nM) and the indicated concentrations of E2 or PROTACs. After incubating for 2 hr at
room temperature or overnight at 4oC, a 50% hydroxy apatite slurry was added to bind
P

P

the receptor/ligand complex and the sample was centrifuged. The resuspended pellet was
then analyzed for tritium activity using scintillation counting and the percent specific
binding affinity was calculated. IC 50 values were obtained using one site competition
R

R

equation (Y = Bottom + (Top-Bottom) / 1 + 10X-LogEC50) provided by the Graph Pad
P

P

Prism® software. Relative binding affinity (RBA) was calculated using the following
equation, RBA = [IC 50 (E2)/IC 50 (sample)] X 100.
R

R

R

R

qRT-PCR:
U

MCF-7 cells were seeded in 6 well plates at a density of 250,000 cells per well
and given 24 hours to attach. The media was changed to 5% Charcoal RPMI for 24 hours
prior to the addition of compounds. Wells (four per condition) were treated with the
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indicated concentrations of compounds for 48 hours. Cells were collected by
trypsinization and stored at -80°C until lysis.
RNA was extracted from the cell pellets using the TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. RNA concentration was determined using
NanoDrop (Thermo Scientific). One microgram of total RNA was employed to create
cDNA utilizing the iScript™ cDNA synthesis kit (Bio-Rad) according to the
manufacturer’s instructions. Reaction conditions: 25µL total volume, 5 minutes at 25°C,
30 minutes at 42°C, 5 minutes at 85°C, followed by a hold at 4°C. The cDNA was stored
at -20°C until qrt-PCR was performed.
The real time reactions (run in triplicate) were performed using an iCycler (BioRad) with the iQ SYBR Green Supermix (Bio-Rad), 200nM of the forward/reverse
primers, and 2µL of cDNA. The following gene-specific primers reported previously [202]
P

P

were used: PR (fwd): 5’-ATCAGGCTGTCATTATGGTGT-3’; PR (rev): 5’AAATTTTCGACCTCCAAGGAC-3’;

β-actin

GCATCCTCACCCTGAAGTAC-3’;
GATAGCACAGCCTGGATAGC-3’.

β-actin

(fwd):

5’-

(rev):

5’-

The reactions for PR were carried out with

annealing at 60℃ for 40 cycles while the reactions for β-actin were carried out with
annealing at 65℃ for 40 cycles. A melting curve analysis was included in each real time
reaction to ensure the specificity of the amplified products. Average cycle threshold (Ct)
values for PR was calculated and normalized to Ct values for β-actin, using the ∆∆Ct
method as an internal control, with the fold-change plotted in GraphPad Prism® and the
product of four independent replicates.
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4.3 Results
U

Initial western blot screening assessed the effects of C-16α PROTACs vs. O17/E2-penta PROTAC (the first generation PROTAC). The result showed (Figure 3.4)
that the C-16α PROTAC was not better at degrading the ER than the original PROTAC;
however, K-1, which has a C-terminal benzyl protecting group, showed better activity
against the ER when compared to K-2, which is not protected (Scheme 3.2 for
structures). Further evaluation using the C- terminus protected O-17/E2-penta PROTAC
(Figure 3.5), indicated a possible role for benzyl protection at the C-terminus of the
pentapeptide in enhancing PROTAC activity. Based on the data from these western blot
studies it was decided that the C-16α position was not ideal for linker attachment and
further length optimization of the PROTAC. As such, addditional PROTACs with the
linker attached at the C-7α position on E2 and a benzyl protecting group at the Cterminus of the pentapeptide was synthesized.
Analysis of C-7 PROTACs
U

C-7 vs C-16 PROTACs:
The C-7α position was chosen for further optimization based on the reported
success of compounds derivatized at that position

[178, 203, 204, 205]
P

. Length optimization
P

was performed at the C-7α position (chapter 3). The different PROTACs were analyzed
for their ability to degrade the ER in a dose dependent manner. ER levels were evaluated
by western blot (Figure 4.1). The C-7α PROTAC containing the DSS extender, (KC-2),
was compared to the C-16α PROTACs, which also has the DSS extender. As observed in
Figure 4.1, K-1 and KC-2 showed similar ability to degrade the ER in a dose dependent
manner, while K-2 did not show a dose dependent increase in ER degradation, again
highlighting a possible role for benzyl protection, as both K-1 and KC-2 contain the
benzyl protecting group.
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Figure 4.1 Dose dependent degradation of ERα by C-16α and C-7α PROTACs: K-1,
K-2 and KC-2 respectively. MCF-7 cells were treated with PROTACs at the indicated
concentrations or with DMSO for 48hrs. Cells were lysed and analyzed via western blot
using anti ERα antibody. The intensities of the bands were quantified (%) using
volumetric densitometry (Quantity One, Bio-Rad). The ERα values were normalized to βactin and DMSO was arbitrarily assigned a value of 100% for comparison purposes. K-1
(C-16 PROTAC- protected C-terminus), K-2 (C-16 PROTAC - unprotected C-terminus),
KC-2 (C-7 PROTAC –benzyl protected C-terminus).

C-7α PROTACs bind to ERα with higher affinity than C-16α PROTACs:
An efficient PROTAC should be able to maintain relatively good binding for the
ER; therefore, competitive binding assays were employed to establish the affinities of the
PROTACs for the ER. Comparison of the binding affinities of selected C-7α PROTACs
with C-16α PROTACs demonstrates that the C-7α PROTACs bind the ER with a
significantly higher affinity than the C-16α PROTACs (Figure 4.2). The dimeric
PROTAC and its monomeric counterparts KC-2 and KC-6 bind to ER with the best
affinity followed by the KC-3 PROTAC. The lower ER-binding affinity of C-16
PROTACs may explain the low ER degradation induced by the C-16 PROTACs. Based
on this data and the data from Figure 3.4, it was concluded that a C-16α based PROTAC
will not be a useful PROTAC strategy.
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Figure 4.2 Relative binding affinities of C-7α PROTACs and C-16α PROTACs.
Competitive ligand binding assays were performed as described in "Materials and
Methods" using purified ERα . The ordinate is Bx/Bo, specifically bound radioligand in
the presence of a given amount of competitor (Bx) divided by specifically bound
radioligand in the absence of competitor. The values represent the mean ± SE and are
represented as percent of that obtained using [3H]-17β estradiol alone.
P

P

Comparison of linker lengths 9, 12 and 16 atoms (KC-1, KC-2 and KC-3 respectively):
The linker between the two moieties of the PROTAC has not been optimized;
therefore, to establish the optimal linker length required for PROTAC activity, five
PROTACs with varying linker lengths were developed (chapter 3). The short linker
PROTACs within the series, KC-1 and KC-2 was compared to KC-3, the mid-length
PROTAC for their ability to degrade the ER in MCF-7 cells. As evidenced in Figure 4.3
western blot data indicated that all PROTACs were capable of degrading the ER at the
concentrations tested.

84

*
Figure 4.3 Analyses of C-7α PROTACs KC-1, KC-2 and KC-3 on ER degradation.
MCF-7 cells were treated with PROTACs at the indicated concentrations or with DMSO
or TAM (5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα
antibody. The intensities of the bands were quantified (%) using volumetric densitometry
(Quantity One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was
arbitrarily assigned a value of 100% for comparison purposes. *data are not typical of
KC-2 at that concentration.

Comparison of linker lengths 16, 19 and 21 atoms (KC-3, KC-4 and KC-5 respectively)
We next wanted to determine the maximum linker length required for PROTAC
activity. Accordingly, the activity of the two longest linker PROTACs, KC-4 and KC-5,
were evaluated along with KC-3 for their ability to degrade the ER. Western blot analysis
indicates a higher level of ER degradation, in a dose dependent manner, in the presence
of KC-3 while KC-4 and KC-5 had very little effect on inducing ER degradation, (Figure
1T

1T

4.4). This suggests that the linkers between the two moieties in KC-4 and KC-5 may be
too long to allow for effective ubiquitin transfer to the ER and as such is unable to recruit
the ER to the proteasome for degradation.
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Figure 4.4 ER degradation by KC-3, KC-4 and KC-5. MCF-7 cells were treated with
PROTACs at the indicated concentrations or with DMSO or TAM (5 μM) for 48hrs.
Cells were lysed and analyzed via western blot using anti ERα antibody. The intensities
of the bands were quantified (%) using volumetric densitometry (Quantity One, BioRad). The ERα values were normalized to β-actin and DMSO was arbitrarily assigned a
value of 1 for comparison purposes.
Effects of low PROTAC dose on the degradation of ER:
Based on the fact that KC-1, KC-2 and KC-3 showed an ability to induce ER
degradation (Figure 4.3); we wanted to investigate the ability of all the PROTACs to
degrade ER at a low dose to determine which was more potent. All PROTACs, with the
exception of KC-3, caused a significant accumulation of the ER that was comparable to
the levels induced by tamoxifen. KC-3 had no significant effect on ER accumulation at
low concentrations (Figure 4.5), suggesting again a possible role for linker length in
PROTAC activity, where KC-3 could represent an optimal spacer between the two
moieties.
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Figure 4.5: Effect on ER degradation at low doses of PROTACs. MCF-7 cells were
treated with PROTACs at the indicated concentrations or with DMSO or TAM (5 μM)
for 48hrs. Cells were lysed and analyzed via western blot using anti ERα antibody. The
intensities of the bands were quantified (%) using volumetric densitometry (Quantity
One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was arbitrarily
assigned a value of 100% for comparison purposes.
Proteasome dependent ER degradation induced by PROTAC:
An appropriately designed PROTAC will require the ubiquitin proteasome
pathway for its action. The proposed mechanism of action of PROTACs, as discussed in
Chapter 2, is that upon binding of the PROTAC to the ER the HIF-1α derived
pentapeptide will be recognized by the pVHL, and the ER-PROTAC complex will be
ubiquitinated and ultimately degraded by the proteasome. In order to examine the
proteasome dependence of the PROTAC, a specific proteasome inhibitor, epoxomicin
(epx), was used (Figures 4.6 and 4.7). The results showed that epoxomicin significantly
inhibited ER degradation at a concentration of 100 nM, indicating that ER degradation by
the PROTACs is proteasome-dependent.
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Figure 4.6 Proteasome dependent degradation of ER by PROTACs. MCF-7 cells
were co-treated with increasing concentrations (10, 50, 100 nM) of the proteasome
inhibitor epoxomicin and PROTACs (25 μM) or E2 (100 nM) or TAM (5 μM, positive
control) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα
antibody. The intensities of the bands were quantified (%) using volumetric densitometry
(Quantity One, Bio-Rad). The ERα values were normalized to β-actin and DMSO was
arbitrarily assigned a value of 100% for comparison purposes.
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25μM KC-3

DMSO

25μM KC-3 + 100 nM Epx

Figure 4.7 Determination of ER degradation via immunofluorescence following
treatment with DMSO, KC-3 PROTAC and proteasome inhibitor epoxomicin
(Epx). MCF-7 cells were treated with DMSO or KC-3 or KC-3 and Epx for 48 hrs. Cells
were then fixed on glass slides and treated with ERα monoclonal antibody, DAPI and
secondary antibody FITC. Green (estrogen receptor-FITC), blue (DAPI nuclear stain)
Protac is dependent on E3 ubiquitin ligase:
It is not sufficient to show proteasome dependence as the ER itself is targeted for
degradation by the UPS. In that case, degradation of ER is tied to E2-ER induced
transcriptional activation of target genes

[206, 207]

. The ability of the PROTACs to be

P

P

specifically recognized by the pVHL E3 ligase complex is key for the action of
PROTACs. In that respect a negative control PROTAC, NC, was synthesized lacking the
critical hydroxyl proline required for pVHL E3 ubiquitin ligase recognition. Evaluation
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of NC and KC-2, that both contain the same linker length suggests that the pVHL is
required for the PROTAC-induced ER degradation (Figure 4.8), as KC-2, which has the
proline residue, was better at inducing ER degradation, than NC.

Figure 4.8 Evaluation of the pVHL dependence for PROTAC activity. MCF-7 cells
were treated with PROTACs at the indicated concentrations or with DMSO, E2 (10 nM),
or TAM (5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα
antibody. NC (negative control PROTAC)
C- vs. N-terminus pentapeptide coupling
Coupling of the pentapeptide to the linker is through the N-terminal Leu residue
while the C-terminal Ile is protected with a benzyl group. To investigate whether the site
for coupling of the linker to the pentapeptide is important for PROTAC activity, an
alternative PROTAC, KC-6, which has an N-terminal Z group and is coupled to the
linker via the C-terminal Ile was developed. KC-2, which has the same linker as KC-6,
but is connected to the linker via the N terminal Leu residue, was compared with KC-6.
Western blot analysis showed that KC-2 was more effective at causing degradation of the
ER, indicating a possible role for peptide orientation in PROTAC activity (Figure 4.9).
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Figure 4.9 N- terminus (KC-2) coupling vs C- terminus (KC-6). MCF-7 cells were
treated with increasing concentrations of PROTACs DMSO or TAM (5 μM) for 48hrs.
Cells were lysed and analyzed via western blot using anti ERα antibody. The intensities
of the bands were quantified (%) using volumetric densitometry (Quantity One, BioRad). The ERα values were normalized to β-actin and DMSO was arbitrarily assigned a
value of 100%.

KC-3 inhibits MCF-7 cell proliferation with an IC 50 similar to that of tamoxifen
R

R

An optimum PROTAC will have the ability to block the proliferation of MCF-7
cells which express high levels of ER. A cell viability assay (MTS) as described in
materials and methods was used to test the effects of PROTACs on MCF-7 cell
proliferation. The dose response curves (Figure 4.10) and the IC 50 for the various
R

R

PROTACs are summarized in Table 4.1. Although a number of PROTACs were capable
of degrading the ER, an investigation of the IC 50 values indicated that the KC-3
R

R

PROTAC was most effective in blocking proliferation of MCF-7 cells, displaying values
comparable to tamoxifen (Table 4.1). This data combined with the degradation data,
suggested that the KC-3 PROTAC may the optimal length PROTAC among the
monomeric PROTACs.
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Figure 4.10 Dose response curves from MTS cell proliferation assay. Following the
treatment of MCF-7 cells with PROTACs or Tamoxifen for 48 hrs, MTS assay was
performed as stated in “Materials and Methods”. The IC 50 values (Table 4.1) were
obtained In GraphPad Prism® (San Diego, USA), from a sigmoid dose-response curve
using a nonlinear regression to a logarithmic function. Data represent at least three
replicates.
R

R

Table 4.1 IC 50 values of PROTACs
R

R

Error

Compound

Dosage

IC 50 (μM)

Tamoxifen

0.50μM to 50µM

27.43

± 2.59

KC-1

1µM to 200µM

139.3

± 49.85

KC-2

1µM to 200µM

94.82

± 18.66

KC-3

1µM to 200µM

25.68

± 5.83

KC-4

1µM to 200µM

> 200

---

KC-5

1µM to 200µM

> 200

---

KC-6

1µM to 200µM

162.9

± 90.23

NC

1µM to 200µM

> 200

---

Dimer

1µM to 200µM

> 200

---

R
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R

95% CI

KC-3 does not induce ER-regulated progesterone receptor (PR) to the same extent as
E2.
To assess the capability of the optimal length PROTAC to influence ER regulated
transcriptional activity, the PR, a known downstream target of the ER, was analyzed
using qRT-PCR. As indicated in Figure 4.11, while E2 resulted in an approximately 10fold increase in PR mRNA relative to control neither tamoxifen nor KC-3 displayed such
a high increase in PR transcription, indicating that the binding of KC-3 to the ER, results
in some agonistic activity, but not to the same extent as E2. A higher concentration of
KC-3 may be required to cause significant PR downregulation.

Figure 4.11 qrt-PCR for progesterone receptor (PR). Graph represents the fold
difference in PR mRNA levels following 48 hr treatment of MCF-7 cells with DMSO,
E2, KC-3 or TAM. The mRNA levels are quantified by normalization to β-actin. Data
represent at least three replicates.
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Activity of KC-7/dimeric PROTAC vs monomeric PROTACs KC-2, KC-6 and NC
A dimeric PROTAC was developed in order to determine whether a PROTAC
strategy that uses two ligands is more efficient at targeting the ER than a monomeric one.
The dimeric PROTAC was evaluated for its action on ER. Western blot analysis and
immunofluorescence was used to analyze the abundance of ER following treatment with
dimeric PROTAC. Data revealed that the dimeric PROTAC had a significant effect on
ER degradation in comparison to its monomeric counterparts; at 10 µM the dimer was
capable of degrading relatively all the ER as indicated in Figure 4.12. The activity of the
dimer also appear to be proteasome dependent, as addition of the proteasome inhibitor
epoxomicin

(Epx)

blocked

the

degradation

of

ER,

as

indicated

by

the

immunofluorescence data (Figure 4.13). The effect of dimer on proliferation was also
evaluated in Table 4.1 and the results indicated, surprisingly, that the dimer had no effect
on proliferation at concentrations up to 200μM.

This may indicate that the dimer

functions as an ER agonist as ER agonists are known to induce ER degradation in concert
with transcriptional activation [208].
P

P
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A.

B.

Figure 4.12 Comparison of KC-7/dimeric PROTAC with monomeric KC-2, KC-6
and NC. MCF-7 cells were with increasing concentrations of PROTACs DMSO or TAM
(5 μM) for 48hrs. Cells were lysed and analyzed via western blot using anti ERα
antibody. The intensities of the bands on western blot films were quantified (%) using
volumetric densitometry (Quantity One, Bio-Rad). The ERα values were normalized to βactin and DMSO was arbitrarily assigned a value of 100% for comparison purposes.
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Media only

10μM dimer

10μM dimer + Epx

Figure 4.13: Analysis of ER status via immunofluorescence following treatment
with dimer PROTAC and proteasome inhibitor epoxomicin (Epx). MCF-7 cells were
treated with DMSO or dimer or dimer and Epx for 48 hrs. Cells were then fixed on glass
slides and treated with ERα monoclonal antibody, DAPI and secondary antibody FITC.
Green (estrogen receptor-FITC), blue (DAPI nuclear stain).
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CHAPTER 5: CONCLUSIONS AND DISCUSSION
5.1 Conclusions and discussion
The data contained herein provides a rational blueprint for the optimization of the
design of an ER-targeting PROTAC. First, data obtained from the original E2-penta (O17 derivative) and C-16α PROTACs demonstrate that derivatizations at the C-16α
position does not improve the ability of the PROTAC to degrade the ER when compared
to the original PROTAC. While the presence of C-C bond instead of an ester bond may
offer increased resistance to in vivo esterases, additional factors, such as binding affinity,
are likewise essential for the judicious design of PROTACs. Interestingly, conjugation at
the C-16α position showed efficient ER degradation for an E2-Geldanamycin hybrid [182],
P

P

probably by disrupting the ER:HSP90 complex. However, the hybrid’s mode of action is
not entirely clear. Consistent with our results, earlier works by Fevig et al. suggested that
the tolerance for long, bulky substituents at the C-16α position is generally not high [209].
P

P

Nonetheless, the lesson from these C-16α PROTACs is that a benzyl protecting group at
the C-terminal of the E3 ubiquitin ligase recognition motif enhances PROTAC activity
compared to unprotected counterparts (Figure 3.4 and 3.5). It is believed that the benzyl
group mimics the ODD region of HIF-1α, which is flanked by polypeptides and as such,
the benzyl group may provide structural stability as well as protect the pentapeptide from
peptidase attack.
Based on the conclusions drawn from the C-16α data, all remaining PROTACs
were synthesized using the benzyl protected E3 ligase recognition motif. Several studies
suggest that the C-7α position can be modified using long linkers without significant loss
of ER binding affinity

[178, 203, 204, 205]
P

. Thus, we derivatized the C-7α position of estradiol
P

to attach linkers of varying lengths for the optimization of the ER-targeting PROTAC.
As Corson et al. point out, a linker has to be long enough to allow flexibility with
the proper interactions between each moiety and its respective protein target, but short
enough to allow for the proper interface between the two units [210]. This is in accordance
P

P

with this data using C-7 derivatized PROTACs. Specifically, it has been shown here that
linker length selection is crucial for promoting the desired PROTAC activity. A linker
that is too short may generate steric hindrance between the two partner proteins,
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preventing efficient ubiquitin transfer to the target. On the other hand, a linker that is too
long may hinder the proper interaction between the E3 ubiquitin ligase and target protein.
While PROTACs with nine and twelve atom linker length, KC-1 and KC-2,
respectively, showed an ability to degrade the ER in a concentration dependent manner,
they are considered less effective than KC-3.

Both KC-1 and KC-2 induced ER

accumulation at low concentrations (500 nM), whereas KC-3, (16-atom length linker),
did not induce significant accumulation of the ER at the concentrations tested. Overall,
KC-3 was the most effective PROTAC as it induced potent ER degradation and
successfully inhibited MCF-7 cell proliferation. Given that most ER regulated genes are
associated with cell proliferation

[158]
P

, increased degradation of the ER by the PROTAC
P

should elicit a lower expression of these genes, inhibiting cell proliferation. The
effectiveness of the KC-3 PROTAC may be due its linker length, wherein the 16-atom
spacer allows for the most effective interaction between ER and the E3 ligase complex.
Another important lesson from these studies concerns the coupling of the ligand
to the pentapeptide. Attachment of the small molecule ligand at the N-terminus of the
HIF-1α pentapeptide is favored for PROTAC activity, as the activity of the PROTAC
decreased when estradiol was attached at the C-terminus of the HIF-1α pentapeptide.
Prior studies revealed a possible role for Tyr in enhancing the interaction of pVHL to the
ODD, while other residues in the ODD were not essential [99]. However, if the residue
P

P

following Ile in the ODD sequence is considered, the Pro structure may be emulated by
the benzyl ring at the C-ternimus of the pentapeptide. Such homology might well
account for the superiority of the N-terminal coupling.
The negative control PROTAC (NC), in which, the critical hydroxy-proline is
replaced with norleucine, did not induce ER degradation. This is significant because its
active counterpart, KC-2, effectively induces ER degradation. Replacement of the
hydroxy-proline abrogrates the interaction between the HIF derived pentapeptide and the
pVHL E3-ligase complex, which is essential for the action of the PROTAC.
The synthesis of a dimeric PROTAC was undertaken in an attempt to improve the
efficiency of the PROTAC strategy. The hypothesis for the design of the dimeric
PROTAC was twofold; first, since dimerization of the ER is a consequence of ligand
binding, association of a dimeric PROTAC with the ER could theoretically mirror this
98

process. Additionally, it was thought that the presence of two ligands on either end of the
HIF pentapeptide should increase the likelihood of an interaction between the PROTAC
and ER. As shown in Figure 4.11, administration of the dimer resulted in very effective
ER degradation at concentrations lower than either of its corresponding monomeric
halves, KC-2 and KC-6.
However, the enhanced ER degradation by dimer did not translate to an effect on
MCF-7 cell proliferation, as demonstrated by the high IC 50 value (Table 4.1). This result
R

R

is similar to a previous study conducted using estrone dimers. The estrone dimers were
incapable of inhibiting breast cancer cell proliferation and displayed IC 50 values similar
R

R

to E2 (>200 μM), leading the authors to postulate that the dimers may function as an E2like compound [200]. This is a reasonable justification of the data seen with the dimeric
P

P

PROTAC, as it too displayed no effect on MCF-7 cell proliferation.
There are a few likely rationales for this discrepancy between the monomeric and
dimeric PROTACs. The first point to consider is that the dimeric PROTAC may bind
either to one ER or to a pair of ERs, resulting in their dimerization. Dimer binding to a
pair of ERs may thus result in agonistic activity similar to the binding of the cognate
ligand. Binding of the cognate ligand results in transcriptional activation of target genes a
process that requires degradation of the ER [208]. Likewise, since the linker between each
P

P

E2 and the HIF-1α pentapeptide is 12 atoms, its inherent flexibility might promote
conformational changes that impede the interaction between the pentapeptide and the E3
ligase. This hindrance of E3-PROTAC interaction would effectively prevent the pVHLmediated ubiquitination and degradation of the ER, while likely leading to transcriptional
activation of target genes and subsequent degradation of the ER. .
While the current dimer PROTAC did not have many advantageous properties,
the binding affinity experiment clearly indicates that the dimer has high affinity for the
ER. This demonstrates the potential for a dimeric PROTAC approach to effectively bind
a target protein, which may result in the efficient recruitment of the target protein to the
E3 ubiquitin ligase. To further validate the dimeric PROTAC approach, a dimeric
PROTAC that uses tamoxifen (antagonist) instead of the agonist (estradiol) should be
explored. This will eliminate the agonistic activity of the dimeric PROTAC that was
observed in this study. To conclusively determine the mode of action of the dimeric
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PROTAC, a negative control dimer should be prepared as well. Additionally, analogous
to what was done for the monomeric PROTACs, it will be interesting to develop dimers
with varying spacers to assess the optimal linker for a dimeric PROTAC.
Therefore, the general conclusions that can be made from these studies are as
follows:
1. An optimum ER-targeting monomeric PROTAC (KC-3) has a spacer of about
16 atoms between the E2, attached at the C-7α position, and the HIF-1α
pentapeptide attached at the N-terminus.
2. The monomeric PROTAC is capable of targeting the ER for degradation in a
proteasome- and pVHL-dependent manner.
3. The optimal PROTAC (KC-3) inhibits proliferation of MCF-7 cells with an
IC 50 similar to that of tamoxifen.
R

R

4. KC-3 alone does not induce the transcription of PR, a downstream target of
the ER, to the same extent as E2.
5. A dimeric PROTAC binds the ER, induces ER degradation and functions in a
proteasome dependent manner, but more studies are needed to validate the
dimeric PROTAC approach.

5.2 Future directions:
U

While this project has provided a great deal of information about the overall
design of an ER-targeting PROTAC, there are still some avenues that are currently
unexplored. For example, what is the potential of an ER-targeting PROTAC as a
therapeutic agent? The effect of ER-targeting PROTACs has only been analyzed in MCF7 cell lines. An analysis of the actions of PROTAC in other ER expressing cells or tissues
such as the uterus and bone should be undertaken in the future to decide whether
PROTAC activity varies from one tissue to the other. This is essential information to
obtain prior to the consideration of an ER-targeting PROTAC as a therapeutic agent.
Also, in terms of therapeutic value, an ER-targeting PROTAC could be of tremendous
100

benefit in cases where resistance to tamoxifen and other antiestrogens have developed, as
the ER is still present and functional in cases of resistance; therefore the activity of KC-3
in tamoxifen/antiestrogen resistant cells should be evaluated.
Additionally, the effect of other ER ligands, such as tamoxifen and genistein
(phytoestrogen) among others, should be explored. Tamoxifen is a known SERM that
binds the ER and displays both antagonistic and agonistic activities depending on its
tissue binding, whereas genistein is a flavone that binds the ER and induce estrogen-like
activities. The mechanism of PROTAC activity currently presumes that any ligand
capable of binding the ER should engender a stable complex facilitating the
ubiquitination and degradation of the ER. Showing that any ligand capable of binding the
ER can target the protein for degradation in a PROTAC-dependent manner will further
strengthen the idea of the approach.
A major drawback to the PROTAC approach as it is utilized currently is the
inclusion of a peptide moeity. The pentapetide as the E3-ligase recognition motif may be
subjected to peptidase activity in vivo, thus replacement of the pentapeptide with a nonpeptide moiety such as a peptidomimetic or a small molecule may be useful in future
design of a PROTAC. This change in the structure of the PROTAC may require a
reoptimization of the linker length.
One of the goals in undertaking this study was to provide a potential blueprint for
the design of PROTACs targeting other proteins. From the studies conducted up to this
point, a few generalizations can be made. First, the PROTAC has been shown to be a
tool that can be used to target any protein with a known ligand specifically to the UPS for
degradation. Secondly, these studies demonstrate that a pentapeptide derived from HIF1α is sufficient for the activity of these PROTACs. Additionally, both the location of the
attachment to the linker and length of the linker moiety are critical for the optimization of
the PROTAC design. A sixteen atom linker proved to be optimal for a monomeric ERtargeting PROTAC; however, more experiments should be conducted to ascertain
whether this linker length will be generally applicable in the design of PROTACs
targeting other proteins.
More specifically, the design of the ER-targeting PROTAC may provide some
insights for the design of other PROTACs targeting nuclear receptors, as they are
101

structurally similar to the ER. Still, adjustments will likely be required to accommodate
the specific ligands for these other protein targets. However, because of the high
homology within the nuclear receptor family, the ER-PROTAC may provide a good
starting point for the design of other nuclear receptor-targeting PROTACs.
Overall, the PROTAC approach could be a useful strategy for probing proteins
with known ligands. More studies need to be done using the current model to develop
PROTACs that target other proteins to validate the general application of this strategy.
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